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A B S T R A C T
Background
The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through diEerent routes,
with advantages and drawbacks of each route. It remains unclear whether the potential harms and additional costs of intravenous (IV)
compared with oral iron are justified.
Objectives
To determine the benefits and harms of IV iron supplementation compared with oral iron for anaemia in adults and children with CKD.
Search methods
In March 2010 we searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL)
in The Cochrane Library, MEDLINE and EMBASE without language restriction.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs in which oral and IV routes of iron administration were compared in adults
and children with CKD.
Data collection and analysis
Two authors independently assessed study eligibility, risk of bias, and extracted data. Results were reported as risk ratios (RR) or risk
diEerences (RD) with 95% confidence intervals (CI) for dichotomous outcomes and for continuous outcomes the mean diEerence (MD)
was used or standardised mean diEerence (SMD) if diEerent scales had been used. Statistical analyses were performed using the random-
eEects model. Subgroup analysis and univariate meta-regression were performed to investigate between study diEerences.
Main results
Twenty eight studies (2098 participants) were included. Risk of bias attributes were poorly performed and/or reported with low risk of
bias reported in 12 (43%) studies for sequence generation, incomplete outcome reporting and selective outcome reporting and in 6 (16%)
studies for allocation concealment. No study was blinded for participants, investigators and outcome assessors but all were considered at
low risk of bias because the primary outcome of haemoglobin was a laboratory outcome and unlikely to be influenced by lack of blinding.
Haemoglobin (22 studies, 1862 patients: MD 0.90 g/dL, 95% CI 0.44 to 1.37); ferritin (24 studies, 1751 patients: MD 243.25 μg/L, 95% CI 188.74
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to 297.75); and transferrin saturation (18 studies, 1457 patients: MD 10.20%, 95% CI 5.56 to 14.83) were significantly increased by IV iron
compared with oral iron. There was a significant reduction in erythropoiesis-stimulating agent (ESA) dose in patients receiving dialysis who
were treated with IV iron (9 studies, 487 patients: SMD -0.76, 95% CI -1.22 to -0.30). There was a high level of heterogeneity in all analyses.
Mortality and cardiovascular morbidity did not diEer significantly, but were reported in few studies. Gastrointestinal side eEects were more
common with oral iron, but hypotensive and allergic reactions were more common with IV iron.
Authors' conclusions
The included studies provide strong evidence for increased ferritin and transferrin saturation levels, together with a small increase in
haemoglobin, in patients with CKD who were treated with IV iron compared with oral iron. From a limited body of evidence, we identified a
significant reduction in ESA requirements in patients treated with IV iron, and found no significant diEerence in mortality. Adverse eEects
were reported in only 50% of included studies. We therefore suggest that further studies that focus on patient-centred outcomes are needed
to determine if the use of IV iron is justified on the basis of reductions in ESA dose and cost, improvements in patient quality of life, and
with few serious adverse eEects.
P L A I N   L A N G U A G E   S U M M A R Y
Iron treatment for adults and children with reduced kidney function
Anaemia oNen occurs in people who have kidney damage, especially those who need dialysis treatment. Anaemia can cause tiredness,
reduce exercise tolerance and increase heart size. A common cause of anaemia is reduced production of a hormone, erythropoietin. Iron
deficiency can make anaemia worse, and reduce response to drugs that stimulate erythropoietin production. Iron can be taken orally
(by mouth) or injected intravenously (via a vein). Intravenous (IV) iron is given under supervision in hospitals. There is uncertainty about
whether IV iron should be used rather than oral iron. In this review of 28 studies (2098 participants), IV iron resulted in higher levels of
haemoglobin (a measure of anaemia) and blood iron levels compared with oral iron, and a reduction in the amount of erythropoietin
required for people receiving dialysis. IV iron resulted in a small number of allergic reactions not seen with oral iron, but oral iron caused
more vomiting, nausea, constipation and diarrhoea than IV iron. No diEerences were found in other outcomes (deaths from any cause,
deaths due to heart disease, quality of life) but these were reported in few (9/28) studies. No studies investigated the impact on patients
who did not need dialysis of coming to hospital to receive IV iron. Although the results confirm that IV iron is more eEective in raising iron
and haemoglobin levels compared with oral iron, we found insuEicient data to determine if the benefits of IV iron are justified by improved
quality of life (fewer gastric upsets) despite the small risk of potentially serious allergic eEects in some patients given IV iron.
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Summary of findings for the main comparison.   Intravenous versus oral iron for adults and children with chronic kidney disease
Intravenous versus oral iron for adults and children with chronic kidney disease
Patient or population: Adults and children with chronic kidney disease 
Settings: Tertiary centres 
Intervention: IV iron 
Comparison: Oral iron
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Oral iron Intravenous iron in CKD patients
Relative ef-
fect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
Haemoglobin: Final or change in all
patients 
g/dL 
Follow-up: 1.3 to 24 months
  The mean Haemoglobin: Final or change
- Haemoglobin in all patients in the in-
tervention groups was 
0.9 higher 
(0.44 to 1.37 higher)
  1862 
(22 studies)
⊕⊕⊕⊝ 
moderate1
 
Ferritin: Final or change in all pa-
tients 
Follow-up: 1.3 to 24 months
  The mean Ferritin: Final or change - Fer-
ritin in all patients in the intervention
groups was 
243.25 higher 
(188.74 to 297.75 higher)
  1751 
(24 studies)
⊕⊕⊕⊝ 
moderate1
 
Transferrin saturation: Final or
change in all patients 
Follow-up: 1.3 to 24 months
  The mean Transferrin saturation: Final
or change - Transferrin saturation in all
patients in the intervention groups was 
10.2 higher 
(5.56 to 14.83 higher)
  1457 
(18 studies)
⊕⊕⊕⊝ 
moderate1,2
 
Study population
316 per 1000 537 per 1000 
(430 to 670)
Medium risk population
Number achieving target haemoglo-
bin or increase of 1 g/dL or more
334 per 1000 568 per 1000 
(454 to 708)
RR 1.7 
(1.36 to 2.12)
1344 
(10 studies)
⊕⊕⊕⊝ 
moderate1,2
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 Significant heterogeneity between studies
2 Studies of variable quality but not suEicient to downgrade overall
 
 
Summary of findings 2.   Intravenous versus oral iron in adults and children with chronic kidney disease: other outcomes
Intravenous versus oral iron in adults and children with chronic kidney disease: other outcomes
Patient or population: Adults and children with chronic kidney disease 
Settings: 
Intervention: IV iron versus oral iron
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Intravenous versus oral iron in CKD pa-
tients: other outcomes
Relative ef-
fect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
End of treatment or change in
ESA dose 
Follow-up: 1.5 to 24 months
  The mean end of treatment or change in
ESA dose in the intervention groups was 
0.76 SDs lower 
(1.22 to 0.3 lower)
  487 
(9 studies)
⊕⊕⊝⊝ 
low1,2
SMD -0.76
(-1.22 to -0.3)
Study population
36 per 1000 42 per 1000 
(13 to 138)
Medium risk population
All-cause mortality 
Follow-up: 1.3 to 24 months
26 per 1000 30 per 1000 
(9 to 100)
RR 1.16 
(0.35 to 3.84)
435 
(5 studies)
⊕⊕⊕⊝ 
moderate3
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Study population
0 per 1000 0 per 1000 
(0 to 0)
Medium risk population
Cardiovascular mortality 
Follow-up: 6 to 24 months
0 per 1000 0 per 1000 
(0 to 0)
RR 3.2 
(0.37 to 27.51)
70 
(2 studies)
⊕⊕⊝⊝ 
low4
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 Only 9/28 studies provided this outcome
2 Significant heterogeneity between studies
3 only 5/28 studies provided this outcome
4 only 2/28 studies reported this outcome
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B A C K G R O U N D
Description of the condition
Anaemia is a common comorbidity in patients with chronic
kidney disease (CKD). The prevalence of anaemia escalates with
increasing severity of kidney dysfunction.In people with CKD
stages 3, 4 and 5D (who need dialysis) approximately 20%,
60% and 70%, respectively, are anaemic (McFarlane 2008). The
primary cause of anaemia in CKD is erythropoietin deficiency,
but iron deficiency can exacerbate the degree of anaemia and
reduce response to erythropoietin-stimulating agents (ESAs). Iron
deficiency may result from deficient dietary intake of the mineral,
decreased gastrointestinal absorption, or frequent blood tests.
In patients receiving haemodialysis (HD), blood losses from the
gastrointestinal tract may reach 11 mL/m2 daily; blood loss through
HD filters average 8 mL/m2/dialysis treatment (Muller-Wiefel 1977).
The chronic inflammation seen in CKD can also reduce iron
absorption from the gut and iron release from iron stores in
macrophages.
Anaemia has a negative impact on exercise capacity, quality of
life, and leN ventricular function. Increasing levels of haemoglobin
results in improved energy levels (Wolcott 1989), better cardiac
performance and ejection fraction (Pappas 2008), and reversal of
increased cardiac output and leN ventricular mass index towards
normal (Cannella 1990). Anaemia has been associated with higher
rates of mortality and morbidity in people with CKD. An increase
in haemoglobin concentration of 1 mg/L was associated with
a 5% decrease in relative risk of mortality and a 4% decrease
in risk of hospitalisation (Locatelli 2004). However, a recent
systematic review of studies assessing the eEects of targeting
higher haemoglobin concentrations in patients with CKD by using
higher doses of ESA showed a significantly higher risk of all-cause
mortality (risk ratio (RR) 1.17) and arteriovenous access thrombosis
(RR 1.34) in the higher haemoglobin target group compared
with the lower haemoglobin group (Phrommintikul 2007). Recent
national (CARI 2008) and international guidelines (Jacobs 2000;
KDOQI 2007; Moist 2008) recommend target haemoglobin levels of
11 mg/L to 12 mg/L in patients with CKD.
Description of the intervention
Iron can be administered via oral or intravenous (IV) routes,
but each has advantages and drawbacks. Oral iron causes
gastrointestinal upset that aEects patient compliance and limits
total intake. IV forms of iron are associated with a variety of
allergic reactions (Bailie 2005) and require administration under
supervision. This need increases the costs of administration and
is inconvenient for patients who are not receiving in-centre HD.
Adverse reactions to IV iron preparations can be life threatening.
Reporting rates for all adverse events associated with IV iron were
29.2, 10.5 and 4.2 reports per million 100 mg dosage equivalents
for iron dextran, ferric gluconate and iron sucrose respectively, and
fatal event reporting rates for the three iron preparations were 1.4,
0.6 and 0 per million (Bailie 2005). IV iron has been linked to an
increased risk of infection, and some experimental data suggest
that IV iron products may impair kidney function.
Evidence from a prospective cohort study (Gillespie 2004) and
randomised controlled trial (RCT) data (Fishbane 1995) suggest
that IV iron leads to significantly higher haemoglobin levels
compared with oral iron in both HD and peritoneal dialysis (PD)
patients (Johnson 2007). In non-dialysis CKD patients, controversy
remains about the most eEective and safe way to provide iron
supplementation (Fishbane 2007). There is also debate about
the most valuable measures to assess iron status, and setting
optimum levels of these measures in patients with CKD to
increase haemoglobin and optimise ESA response. Parameters
used to monitor iron status include serum ferritin levels, transferrin
saturation (TSAT), per cent of hypochromic red blood cells,
and reticulocyte haemoglobin content. Reticulocyte haemoglobin
content is considered to be a highly sensitive marker of functional
iron deficiency (Mittman 1997), but is not routinely measured.
How the intervention might work
Iron deficiency anaemia is common in patients with CKD whether
or not ESAs are administered. Iron deficiency is the most
common cause of hyporesponsiveness to ESAs (Kwack 2006).
ESAs accelerate erythropoiesis by increasing iron utilisation and
depleting iron stores. Optimal eEicacy of ESAs depends on
availability of adequate iron stores to achieve and maintain target
haemoglobin levels. Haemoglobin levels may increase in patients
with CKD given iron therapy even when standard tests do not
indicate iron deficiency. Patients with CKD stage 5D require higher
targets for ferritin and TSAT levels compared with patients whose
kidney function is normal to achieve increased haemoglobin levels.
Two studies targeting ferritin levels of 400 ng/mL or 30% to 50%
TSAT resulted in significant reductions in the ESA dose required
to maintain haemoglobin levels compared with targeting a ferritin
level of 200 ng/mL or TSAT levels of 20% to 30% (Besarab 2000;
DeVita 2003). However, such high ferritin and TSAT levels increase
the risk of iron overload and its associated complications. The
Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines
(KDOQI 2007) and the Canadian (Madore 2008) and European
guidelines (Jacobs 2000) recommend serum ferritin of > 200 ng/
mL and TSAT > 20% in patients receiving HD. In other patients
with CKD, serum ferritin levels > 100 ng/mL and TSAT > 20% are
recommended.
Why it is important to do this review
At present, most HD patients routinely receive IV iron to maintain
iron levels. Patients on PD, and those with CKD who do not
require dialysis, receive oral iron. However, it remains unclear
whether these are the correct indications for IV iron and if the
potential hazards, additional costs, and inconvenience to patients
of IV compared with oral iron are justified in terms of improved
cardiac function, exercise tolerance and quality of life, increased
iron stores and haemoglobin levels, and reduced requirements for
ESAs. A recent systematic review identified seven small studies
comparing IV and oral iron in HD patients (Rozen-Zvi 2008).
Significant heterogeneity was found among studies; three showed
no significant diEerence between IV and oral routes of iron
administration. Meta-regression identified significant associations
between haemoglobin response and lower baseline haemoglobin,
and lower ESA and IV iron doses. Among patients with CKD on
dialysis, a small benefit was noted with IV iron (0.31 g/dL), which is
of uncertain clinical significance.
In this review, we aimed to explore all possible causes of
heterogeneity of study results in detail by subgroup analysis and to
further investigate the eEects of IV iron in patients with CKD who
were not on dialysis.
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O B J E C T I V E S
Our objective was to determine the benefits and harms of IV
iron supplementation compared with oral iron for anaemia in
patients with CKD, treated with HD, PD, not receiving dialysis
and post transplant. The review aimed to examine the eEects of
these interventions on iron parameters, achieving target levels of
haemoglobin, reducing doses of ESA required, and on mortality,
hospitalisation, cardiac function, quality of life, and to determine
adverse eEects of the therapies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and quasi-RCTs (studies in which allocation to
treatment was obtained by alternation, use of alternate medical
records, date of birth or other predictable methods) in which oral
and IV routes of administration of iron were compared in patients
with CKD.
Types of participants
Inclusion criteria
We included adult and paediatric patients with CKD (stages 3 to
5D; glomerular filtration rate (GFR) < 60 mL/min/1.73 m2). Studies
in patients receiving HD, PD, or those not requiring dialysis, were
included. Studies of kidney transplant patients were also included.
Exclusion criteria
Studies of iron administration in patients comparing diEerent IV or
oral iron preparations and diEerent doses of the same IV or oral
preparation were excluded. Studies in patients with acute kidney
injury were excluded.
Types of interventions• We examined diEerent IV iron supplements (iron sucrose,
dextran, ferric gluconate, ferumoxytol) and oral iron
preparations, such as ferrous fumarate, and sulphate-including
preparations that contain folic acid or vitamin C or both.• We included studies using diEerent doses and durations of IV
iron compared with oral iron preparations provided that the
control group received oral iron supplements only.
Types of outcome measures
Primary outcomes• Haemoglobin* Per cent achieving target haemoglobin level* Time to achieve target haemoglobin* Mean change of haemoglobin from baseline* Increase in haemoglobin > 10 g/L or other target during study• Iron* Per cent achieving target levels of iron (ferritin, TSAT, per cent
of hypochromic red blood cells)
Secondary outcomes• ESA* ESA dose* Numbers of patients needing to increase ESA dose or receive
one or more blood transfusions* Reduction in required ESA dose• All-cause mortality• Cardiovascular mortality and morbidity• Numbers of non-dialysis patients needing to commence dialysis• Haematocrit (%)• Reticulocyte haemoglobin concentration• Any adverse events* Adverse eEects of oral iron* Adverse eEects of IV iron supplements including
hypersensitivity reactions* Number of patients needing to cease oral or IV supplements
because of adverse eEects
Other outcomes• Hospitalisation (other than for iron infusions and dialysis)• Exercise tolerance• Quality of life• LeN ventricular function• Sexual function• Nutritional status• Malignancy• Risk of infections• Adherence to therapy• Change in GFR in non-dialysis patients• Time to achieve target iron levels• Numbers and costs of hospitalisations/professional supervision
required for IV iron supplements• C-reactive protein (CRP), other inflammatory markers• Iron overload (as defined by the triallists).
Search methods for identification of studies
Electronic searches
In March 2010 we searched the following electronic databases
(Appendix 1).
1. The Cochrane Renal Group's specialised register and the
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library. CENTRAL contains the handsearched
results of conference proceedings from general and speciality
meetings. This is an ongoing activity of the Cochrane
Collaboration and is both retrospective and prospective (Master
List 2009). Therefore, we did not specifically search conference
proceedings. Please refer to The Cochrane Renal Group's Module
in The Cochrane Library for the most up-to-date list of conference
proceedings (Renal Group 2011).
2. MEDLINE (from 1966) using the optimally sensitive strategy
developed for the Cochrane Collaboration for the identification
of RCTs (Lefebvre 2008) with a search strategy developed
with input from the Cochrane Renal Group's Trials Search Co-
ordinator.
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3. EMBASE (from 1980) using the optimally sensitive strategy
developed for the Cochrane Collaboration for the identification
of RCTs (Lefebvre 2008) with a search strategy developed
with input from the Cochrane Renal Group's Trials Search Co-
ordinator.
Searching other resources
1. Reference lists of nephrology textbooks, review articles and
relevant studies
2. Letters to investigators seeking information about unpublished
or incomplete studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and
abstracts of studies that were potentially relevant to the review.
The titles and abstracts were screened independently by JA and
EH, who discarded studies that were not applicable. However,
studies and reviews that might include relevant data or information
on studies were retained initially. Two authors independently
assessed retrieved abstracts, and where necessary the full text, of
these studies to determine which satisfied the inclusion criteria.
Data extraction and management
Data extraction and assessment of the risk of bias were performed
independently by the same authors using standardised data
extraction forms. Studies reported in non-English language
journals were translated before assessment. Where more than
one publication of one study existed, only the publication with
the most complete data was included. Where relevant outcomes
were only published in earlier versions, these data were used.
Any discrepancy between published versions was highlighted.
Any further information required from the original author was
requested by written correspondence and any relevant information
obtained in this manner was included in the review. Disagreements
were resolved in consultation with a third author.
Assessment of risk of bias in included studies
The following items were assessed using the risk of bias assessment
tool (Higgins 2008) (see Appendix 2).
• Was there adequate sequence generation?• Was allocation adequately concealed?• Was knowledge of the allocated interventions adequately
prevented during the study?• Were incomplete outcome data adequately addressed?• Are reports of the study free of suggestion of selective outcome
reporting?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e:ect
For dichotomous outcomes (number reaching target haemoglobin,
death) results were expressed as risk ratios (RR) with 95%
confidence intervals (CI). Risk diEerences (RD) with 95% CI
were calculated for adverse eEects. Where continuous scales
of measurement were used to assess the eEects of treatment
(haemoglobin level, rise in haemoglobin, iron parameters) the
mean diEerence (MD) was used, or the standardised mean
diEerence (SMD) if diEerent scales had been used (end of study
ESA dose). Either final levels or change in levels were included in
meta-analyses of continuous scales of measurement. When both
measures are provided in a study, final levels were included. Where
standard deviations (SD) for changes in levels or initial or final levels
were missing and not available from triallists, these were imputed
(Higgins 2008).
Unit of analysis issues
Cross-over studies were thought likely to be inappropriate means
of examining IV and oral iron because of carry over eEects related
to achieved haemoglobin levels and iron parameters. Therefore,
only data from the first period of cross-over studies were included
where these were reported separately, and included all or most
patients who completed the first period, rather than only those who
completed both treatment periods.
Dealing with missing data
Where necessary, we contacted triallists to request missing
patient data due to loss to follow-up and exclusion from study
analyses in an eEort to conduct intention-to-treat analyses. Eight
authors responded to our requests. Where missing dichotomous or
continuous data were few, and unlikely to aEect the overall results,
we analysed available data.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
The search strategy included searching major databases,
conference proceedings and prospective trial registers without
language restriction in an attempt to reduce publication bias
related to failure of authors to publish negative results or inability
to publish negative results in journals indexed in major databases.
When suEicient studies were available, attempts were made to
assess for publication bias using funnel plots. Where multiple
publications of the same study were identified, data were included
from the most recent publication, and preferably, the definitive
publication. However, all publications were reviewed to identify
outcomes not reported in the index publication in an attempt to
reduce outcome reporting bias.
Data synthesis
Data were pooled using the random-eEects model for dichotomous
and continuous data.
Subgroup analysis and investigation of heterogeneity
To explore clinical diEerences among studies that could influence
the magnitude of the treatment eEect for the primary outcomes of
diEerences in ferritin, TSAT and haemoglobin, subgroup analyses
and univariate meta-regression were performed using STATA
soNware (StataCorp LP, Texas, USA) using restricted maximum-
likelihood to estimate between study variance. The potential
sources of variability were defined a priori and were related
to study rationale (CKD stage, whether aiming to increase or
maintain haemoglobin, concurrent use of erythropoietin co-
intervention, timing of initiation of erythropoietin co-intervention),
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dose delivered and duration of IV and oral iron therapy, and study
sponsorship. Where subgroup analysis findings suggested that
more than one factor could influence the magnitude of observed
diEerences, we planned to conduct multivariate meta-regression.
Underlying cause of end-stage kidney disease (ESKD), baseline iron
status, and previous iron therapy were not examined in subgroup
analyses because most studies did not provide this information.
All studies, except one paediatric study, included adults of similar
ages so diEerent age groups could not be examined in subgroup
analyses. Only one study (Li 2008 PD) included solely PD patients so
it was not possible to examine diEerent types of renal replacement
therapy in subgroup analyses.
Sensitivity analysis
Sensitivity analyses were performed to test decisions where
inclusion of a study, with a much higher MD in haemoglobin, might
have altered meta-analysis results.
R E S U L T S
Description of studies
Results of the search
A total of 520 study reports were retrieved aNer searching
the Cochrane Renal Group’s specialised register to March 2010,
CENTRAL (in The Cochrane Library Issue 1, 2010), MEDLINE (to
October week 5 2008) and EMBASE (to week 45 2008). The Cochrane
Renal Group’s specialised register includes conference proceedings
from nephrology meetings and is updated regularly, so searches of
other databases aNer the initial search were not required. Search
results are shown in Figure 1. Following full text review of 76
potentially eligible reports, 28 were excluded and 28 studies (45
reports) were identified as eligible for inclusion. Three additional
studies were identified; two through trial registration databases
(Agarwal 2008; Monofer 2010 CKD) and one from publication
of the protocol (Mudge 2009 TX), but we did not identify any
corresponding publication of results. Therefore, 28 studies (45
reports) were included in this review.
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Figure 1.   Flow diagram of studies included in the systematic review
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Included studies
Of the 28 included studies, 27 (2078 participants) were parallel
group studies, and one (20 patients) was a cross-over study
(Strickland 1977 HD). With one exception, studies only included
adult patients. Warady 2002 HD included only children on HD.
Seventeen studies (Broumand 1998 HD; Erten 1998 HD; Fishbane
1995 HD; Fudin 1998 HD; Hussain 1998 HD; Kotaki 1997 HD; Li 2008
PD; Li 2008 HD; Lye 2000 HD; Macdougall 1999 HD,PD; Michael 2007
HD; Provenzano 2009 HD; Souza 1997 HD; Strickland 1977 HD; Svara
1996 HD; Wang 2003 HD; Warady 2002 HD) included patients on
HD or PD. Li 2008 PD included only patients receiving PD. Ahsan
1997 TX (12 patients) included only patients who were in the early
phase of post kidney transplantation. Results from this study were
pooled with studies of dialysis patients. Nine studies (Agarwal 2006
CKD; Aggarwal 2003 CKD; Charytan 2005 CKD; Leehey 2005 CKD;
McMahon 2009 CKD; Spinowitz 2008 CKD; Stoves 2001 CKD; Qunibi
2007 CKD; Van Wyck 2005 CKD) included non-dialysis patients
(CKD stages 3 to 5) and Macdougall 1996 HD,PD,CKD (20 patients)
included both dialysis and non-dialysis patients. Ten studies were
available only as abstracts (Ahsan 1997 TX; Broumand 1998 HD;
Erten 1998 HD; Leehey 2005 CKD; Lye 2000 HD; Macdougall 1999
HD,PD; Michael 2007 HD; Qunibi 2007 CKD; Souza 1997 HD; Wang
2003 HD). Nineteen studies were designed to increase haemoglobin
levels  and four studies were  designed to maintain haemoglobin
stability in iron replete patients and decrease ESA dose (Fishbane
1995 HD; Kotaki 1997 HD; Michael 2007 HD; Warady 2002 HD).
The duration of follow-up ranged from 35 days to 26 months.
Studies compared diEerent oral and IV iron preparations. The
oral iron agents investigated were ferrous sulphate (20 studies),
ferrous fumarate (four studies), ferrous succinate (two studies), and
unnamed agents in two studies. The IV iron agents investigated
were iron sucrose (12 studies), iron dextran (six studies),
ferumoxytol (two studies), sodium ferric gluconate complex (four
studies), ferricarboxymaltose (one study), ferric citrate (one study)
and ferric hydroxide polymaltose (one study). The IV iron agent
was not reported in Kotaki 1997 HD. The calculated total dose of
elemental iron ranged from 4347 to 63,000 mg in the oral iron
groups and from 500 to 4800 mg in the IV iron groups. Erten 1998
HD included two IV iron treatment groups. Data from patients who
received the higher total dose of IV iron were included in the meta-
analyses.
Nineteen studies included patients on ESAs. ESA therapy was
started at study commencement in six studies  (Aggarwal 2003
CKD; Charytan 2005 CKD; Hussain 1998 HD; Lye 2000 HD;
Macdougall 1996 HD,PD,CKD; Stoves 2001 CKD) and before study
commencement in 12 studies (Broumand 1998 HD; Erten 1998
HD;  Fishbane 1995 HD; Kotaki 1997 HD; Leehey 2005 CKD; Li
2008 PD; Li 2008 HD; Macdougall 1999 HD,PD; Michael 2007 HD;
Provenzano 2009 HD; Svara 1996 HD; Warady 2002 HD). It was
unclear when ESA treatment was commenced in Wang 2003 HD.
Five studies reported that no included patients received ESA
treatment  (Agarwal 2006 CKD; Ahsan 1997 TX; Fudin 1998 HD;
McMahon 2009 CKD; Strickland 1977 HD), but four studies indicated
that varying proportions or patients received ESAs (Spinowitz 2008
CKD; Qunibi 2007 CKD; Souza 1997 HD; Van Wyck 2005 CKD).
The outcomes reported in studies are presented in Figure 1. Final
haemoglobin, serum ferritin and TSAT levels were reported in 17, 21
and 15 studies respectively; some of these studies also reported on
change in haemoglobin, ferritin or TSAT. Change in haemoglobin,
serum ferritin and TSAT, but not final levels, were reported in
five, four and three studies respectively. Four studies reported
final haematocrit levels but not haemoglobin levels (Ahsan 1997
TX; Fishbane 1995 HD; Kotaki 1997 HD; Svara 1996 HD). Only five
studies reported all-cause mortality (Fishbane 1995 HD; Fudin 1998
HD; McMahon 2009 CKD; Provenzano 2009 HD: Stoves 2001 CKD);
two studies reported on cardiovascular mortality (Stoves 2001
CKD; Fudin 1998 HD); and two studies reported on quality of life
assessment (Agarwal 2006 CKD; Van Wyck 2005 CKD). Thirteen
studies reported on adverse events (Agarwal 2006 CKD; Aggarwal
2003 CKD; Charytan 2005 CKD; Fishbane 1995 HD; Hussain 1998
HD; Li 2008 PD; Li 2008 HD; Provenzano 2009 HD; Qunibi 2007 CKD;
Spinowitz 2008 CKD; Stoves 2001 CKD; Strickland 1977 HD; Van
Wyck 2005 CKD).
Funnel plots (data not shown) to examine for publication bias
in reporting of haemoglobin, ferritin and TSAT levels suggested
that some small studies which showed no significant benefit of IV
compared with oral iron were not identified in the literature search.
Ten studies were available only as abstracts. Subgroup analyses
that compared the change in haemoglobin or final haemoglobin
in full text papers and in abstracts showed that the MD was
slightly higher in studies reported as abstracts (MD 0.64 g/dL,
95% CI 0.35 to 1.78) compared with studies reported as full
papers (MD 1.06 g/dL; 95% CI 0.35 to 1.78). This raises the
possibility that studies remained unpublished because of the
limited demonstrated benefit of IV iron compared with oral iron.
Excluded studies
Twenty eight reports were excluded aNer full text review. These
included three reports for the study by Lye 1997 that compared
intramuscular and oral preparations; the remainder compared
diEerent doses and preparations given IV. Three  reports of
two studies applied non-randomised sequential designs (Ahsan
2000; Johnson 2001); one study included non-randomised patients
(Allegra 1991), and one study was a non-randomised comparator
study of oral and IV iron (Jenq 2005).
Risk of bias in included studies
The assessment of risk of bias is shown in Figure 2 and Figure 3.
Figure 2 shows relative proportional rankings of studies for each
risk of bias indicator. Figure 3 shows the risk of bias items for
individual studies.
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Figure 2.   Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Figure 3.   Risk of bias summary: Review authors' judgements about each risk of bias item for each included study
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Figure 3.   (Continued)
 
Allocation
Randomisation of sequence generation was reported adequately in
12 studies (Agarwal 2006 CKD: Fudin 1998 HD: Leehey 2005 CKD; Li
2008 PD: Li 2008 HD: Macdougall 1996 HD,PD,CKD; McMahon 2009
CKD; Spinowitz 2008 CKD; Stoves 2001 CKD; Strickland 1977 HD; Van
Wyck 2005 CKD; Warady 2002 HD). Randomisation method was not
reported in 16 studies. Six studies reported allocation concealment
adequately (Agarwal 2006 CKD; Leehey 2005 CKD; Macdougall 1996
HD,PD,CKD; Provenzano 2009 HD; Spinowitz 2008 CKD; Van Wyck
2005 CKD), and for two studies this was inadequately reported
(Fudin 1998 HD; Lye 2000 HD). Allocation concealment was unclear
in 20 studies.
Blinding
Although none of the included studies reported methods of
blinding for participants, investigators or outcomes assessors, all
were considered to be at low risk of blinding bias. This was
because most primary outcomes were laboratory measurements
conducted independently from study investigators and unlikely to
be influenced by blinding.
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Incomplete outcome data
Outcomes data reporting was considered to be complete with
a low risk of bias in 12 studies (Agarwal 2006 CKD; Broumand
1998 HD; Erten 1998 HD; Kotaki 1997 HD; Li 2008 PD; Li 2008
HD; Macdougall 1996 HD,PD,CKD; McMahon 2009 CKD; Provenzano
2009 HD; Spinowitz 2008 CKD; Van Wyck 2005 CKD; Warady 2002
HD). Six studies (Charytan 2005 CKD; Fishbane 1995 HD; Fudin 1998
HD; Strickland 1977 HD; Stoves 2001 CKD; Svara 1996 HD) reported
that from 7% to 36% of patients were excluded from the analyses,
so were considered to be at high risk of bias. The risk of bias was
unclear in 10 studies because there was insuEicient information
provided to determine if data from all patients who entered the
study were included in the analysis.
Selective reporting
We identified 12 studies (Agarwal 2006 CKD; Fishbane 1995
HD; Kotaki 1997 HD; Li 2008 PD; Li 2008 HD; Macdougall 1996
HD,PD,CKD; McMahon 2009 CKD; Provenzano 2009 HD; Spinowitz
2008 CKD; Svara 1996 HD; Van Wyck 2005 CKD; Warady 2002
HD) that were considered to have reported all outcomes based
on the detailed protocols described in the trial methods. Seven
studies  (Aggarwal 2003 CKD; Broumand 1998 HD; Charytan 2005
CKD; Leehey 2005 CKD; Qunibi 2007 CKD; Stoves 2001 CKD;
Strickland 1977 HD) reported outcomes incompletely so that they
either could not be meta-analysed or included only with imputed
SDs. It was unclear if outcomes were selectively reported in nine
studies.
Other potential sources of bias
Twelve studies (Agarwal 2006 CKD; Charytan 2005 CKD; Leehey
2005 CKD; McMahon 2009 CKD; Michael 2007 HD; Provenzano
2009 HD; Qunibi 2007 CKD; Spinowitz 2008 CKD; Stoves 2001 CKD;
Strickland 1977 HD; Van Wyck 2005 CKD; Warady 2002 HD) reported
receiving monetary support from pharmaceutical companies; 16
studies did not report study funding.
E:ects of interventions
See: Summary of findings for the main comparison Intravenous
versus oral iron for adults and children with chronic kidney disease;
Summary of findings 2 Intravenous versus oral iron in adults and
children with chronic kidney disease: other outcomes
In most studies, the primary outcome was final haemoglobin level
or change in haemoglobin with final level. Changes in ferritin
and TSAT were common secondary outcomes. End of treatment
and change in values were combined in the meta-analyses of
continuous variables. Where final results and changes in results
were both reported, final levels were included in the meta-analyses.
Changes in values in one or more of haemoglobin, ferritin and TSAT
from six studies (Agarwal 2006 CKD; Charytan 2005 CKD; Leehey
2005 CKD; Michael 2007 HD; Qunibi 2007 CKD; Souza 1997 HD)
were meta-analysed. Data from Strickland 1977 HD could not be
meta-analysed because both arms of the cross-over study were
combined. Data from Stoves 2001 CKD were reported as median
with interquartile ranges so could not be included in meta-analyses
of final haemoglobin, ferritin or final ESA dose. Where they were
not reported by study authors (Broumand 1998 HD; Charytan 2005
CKD; Leehey 2005 CKD; Qunibi 2007 CKD), SDs were imputed using
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008) to enable meta-analysis
(Broumand 1998 HD; Charytan 2005 CKD; Leehey 2005 CKD; Qunibi
2007 CKD). In subgroup analyses no significant diEerences in results
were detected on testing for interaction among studies in which SDs
were imputed and other studies (Table 1; Table 2; Table 3).
E:ect on haemoglobin concentrations of IV iron compared
with oral iron
Final haemoglobin level or change (g/dL) in haemoglobin were
reported in 22 studies. Haemoglobin was significantly increased
by IV iron compared with oral iron (Analysis 1.1 (22 studies, 1862
patients): MD 0.90 g/dL, 95% CI 0.44 to 1.37) in all patients, and
in the subgroups of dialysis patients (13 studies, 828 patients:
MD 1.16 g/dL, 95% CI 0.30 to 2.02), and non-dialysis patients (8
studies, 1020 patients: MD 0.45 g/dL, 95% CI 0.24 to 0.66) (Table
1). There were high levels of heterogeneity in all analyses (58%
to 97%) which persisted when a fixed-eEect model was used for
analysis. Excluding a study of 26 months treatment and MD 4.92 g/
dL (Fudin 1998 HD) did not reduce heterogeneity. Further analyses
of heterogeneity are addressed in the following sections.
Number reaching target haemoglobin or increasing
haemoglobin by 1 g/dL
The numbers of patients reaching target haemoglobin or increasing
haemoglobin by at least 1 g/dL were each reported in 10 studies.
Target haemoglobin or an increase in haemoglobin by 1 g/dL or
more was achieved by significantly more patients receiving IV iron
compared with oral iron (Analysis 1.2 (10 studies, 1344 patients): RR
1.70, 95% CI 1.36 to 2.12).
E:ect on serum ferritin concentrations of IV iron compared
with oral iron
Final ferritin level or change (μg/L) in serum ferritin levels were
reported in 24 studies. Ferritin levels were significantly increased
by IV iron compared with oral iron in all patients (Analysis 1.3 (24
studies, 1751 patients): MD 243.25 μg/L, 95% CI 188.74 to 297.75)
and in the subgroups of dialysis (16 studies, 960 patients: MD 246.57
μg/L, 95% CI 162.21 to 330.92) and non-dialysis patients (7 studies,
771 patients: MD 229.01 μg/L, 95% CI 157.97 to 300.05) (Table 2).
There was a high level of heterogeneity in all analyses (91% to 93%).
E:ect on % TSAT levels of IV iron compared with oral iron
End of treatment or change in TSAT levels were reported in 18
studies. TSAT was significantly increased by IV iron compared with
oral iron in all patients (Analysis 1.4 (18 studies, 1457 patients): MD
10.20%, 95% CI 5.56 to 14.83) and in the subgroups of dialysis (11
studies, 709 patients: MD 13.97%, 95% CI 6.00 to 21.34) and non-
dialysis patients (6 studies, 729 patients): MD 6.89%, 95% CI 3.65
to 10.12) (Table 3). There was a high level of heterogeneity in all
analyses (80% to 96%).
E:ect on ESA administration of IV iron compared with oral iron
Nine studies reported final dose or change in ESA dose. There was
a significant reduction in ESA dose in patients treated with IV iron
compared with oral iron (Analysis 2.1 (9 studies, 487 patients): SMD
-0.76, 95% CI -1.22 to -0.30), and a high level of heterogeneity (I2 =
81%).
Two studies reported on the numbers of patients for whom an
increase in ESA dose was required, but no significant diEerence was
found (Analysis 2.2 (2 studies, 45 patients): RR 0.34, 95% CI 0.11 to
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1.06). Four studies reported on numbers of patients in whom ESA
dose could be reduced or ceased; no significant diEerence on this
outcome was found between IV and oral iron therapy (Analysis 2.3
(4 studies, 150 patients): RR 2.02, 95% CI 0.69 to 5.91), although
there was considerable heterogeneity (I2 = 79%).
E:ects of IV iron compared with oral iron on other outcomes
All-cause mortality was reported in five studies with no significant
diEerence reported between IV and oral iron therapy (Analysis 2.4
(5 studies, 435 patients): RR 1.16, 95% CI 0.35 to 3.84).
Cardiovascular mortality was reported in two studies with no
significant diEerenced detected between IV and oral therapy
(Analysis 2.5 (2 studies, 70 patients): RR 3.20, 95% CI 0.37 to 27.51).
Three studies reported on the need for non-dialysis patients to
commence dialysis and found no significant diEerence between IV
and oral iron for this outcome (Analysis 2.6 (3 studies, 282 patients):
RR 0.69, 95% CI 0.28 to 1.71).
Four studies reported results for haematocrit rather than
haemoglobin. When combined, results from these four studies
indicated that haematocrit levels did not diEer significantly
between IV and oral therapies (Analysis 2.7.1 (4 studies, 152
patients): MD 1.18%, 95% CI -2.17 to 4.52; I2 = 96%). However
exclusion of Kotaki 1997 HD, in which haematocrit levels were to
be kept stable, reduced heterogeneity and resulted in a significant
increase in haematocrit with IV iron (Analysis 2.7.2 (3 studies, 121
patients): MD 2.43%, 95% CI 0.42 to 4.44).
Four studies reported reticulocyte haemoglobin content (CHr) and
found a significant increase between IV and oral iron therapies for
this outcome (Analysis 2.8 (4 studies, 506 patients): MD 0.67, 95% CI
0.29 to 1.05).
In two studies, no significant diEerences were reported at study
end in creatinine or GFR, so results could not be meta-analysed
(Aggarwal 2003 CKD; McMahon 2009 CKD).
Two studies reported results of quality of life assessment. Agarwal
2006 CKD reported that the SF12 physical composite score
improved by 4.8% in patients treated with IV iron, but there
was no change in patients treated with oral iron. KDQOl items
- improvement in the ability to do moderate activities and
undertake work; and satisfaction with sex life - were reported to be
significantly improved among patients treated with IV iron. Scores
for a number of factors, including feelings of imposing a burden on
family, were significantly lower in patients who received IV iron. In
contrast, Van Wyck 2005 CKD found no significant diEerences when
health concept categories in the SF36 instrument were applied.
Although nine studies reported that patient adherence to oral iron
was assessed, only two provided numerical data (Charytan 2005
CKD; Van Wyck 2005 CKD). Mean adherence rates for IV iron therapy
were 95% and 97% respectively, and adherence to oral iron therapy
was 85% and 88%.
Exploration of heterogeneity using subgroup analyses: E:ect
of di:erent doses of IV or oral iron on haemoglobin, ferritin
and TSAT
Subgroup analysis using testing for interaction was applied to
investigate the eEects of diEerent total doses of IV iron (≤ 1000 mg,
1000 to 2000 mg, > 2000 mg), diEerent doses/month of IV iron (≤
400 mg/month, > 400 to 700 mg/month, > 700 mg/month), diEerent
total doses of oral iron (< 12,000 mg, 12,000 to 30,000 mg, > 30,000
mg) and diEerent doses/month of oral iron (< 4000 mg/month, 4000
to <6000 mg/month, ≥ 6000 mg/month) on levels of haemoglobin,
ferritin and TSAT. These values were chosen based on tertiles of
doses investigated in the included studies. Results for the outcomes
of haemoglobin, ferritin and TSAT are shown in Table 1; Table 2 and
Table 3 respectively.
There were no significant diEerences in total dose administered of
IV iron and of IV iron/month between subgroups for haemoglobin
(Figure 4) and TSAT. The MD in ferritin levels increased significantly
when total IV iron dose was increased, but not in relation to
increased IV iron dose/month (Figure 5).
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Figure 4.   Metaregression of standard mean di:erences in haemoglobin for intravenous dose of iron/month
 
 
Figure 5.   Metaregression of standard mean di:erences of ferritin and dose of intravenous iron/month and total
dose of intravenous iron
 
There were no significant diEerences in total oral iron dose
administered and oral iron dose/month between subgroups for
ferritin or TSAT. The MD in haemoglobin escalated with increase
in oral iron/month (Figure 6) but not for total oral iron dose. The
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diEerence for oral iron/month was eliminated when one study with
a very high MD (Fudin 1998 HD) was excluded from the analysis.
 
Figure 6.   Metaregression of standard mean di:erence in haemoglobin for oral iron intake/months
 
Exploration of heterogeneity using subgroup analyses: E:ects
of erythrocyte-stimulating agents (ESAs) on the response to
iron therapy
Subgroup analysis was used to investigate the diEerential response
of haemoglobin, ferritin and TSAT levels in patients who did or did
not receive ESAs during iron therapy, and in patients who began ESA
therapy at study commencement compared with those already on
ESA. No significant diEerences were found among subgroups (Table
1; Table 2; Table 3). Haemoglobin, ferritin and TSAT levels were
increased by IV iron compared with oral iron in patients irrespective
of if or when ESAs were administered.
Other subgroup analyses
Exclusion of two studies (Michael 2007 HD; Warady 2002 HD) that
were designed to maintain stable haemoglobin levels from the
haemoglobin meta-analysis, and four studies (Fishbane 1995 HD;
Kotaki 1997 HD; Michael 2007 HD; Warady 2002 HD) designed to
maintain stable haemoglobin levels from the ferritin and TSAT
meta-analyses, did not alter heterogeneity (84% to 96%). No
significant diEerences were found on testing for interaction (Table
1; Table 2; Table 3).
Subgroup analyses of study duration (≤ 2 months, ≥ 2 to 4
months, ≥ 4 months) showed no significant diEerence on testing
for interaction (Table 1; Table 2; Table 3) for final levels or changes
in levels in haemoglobin, ferritin or TSAT. There was significant
heterogeneity.
Pharmaceutical company sponsorship of studies was associated
with a significantly smaller increase in haemoglobin level
compared with studies that did not report sponsorship status
(Table 1). Exclusion of a study with a high MD (Fudin 1998 HD; MD
4.92) did not eliminate the diEerence. There were no significant
diEerences for ferritin or TSAT levels (Table 2; Table 3).
Adverse e:ects
We identified 12 studies that provided some information on
adverse eEects of therapy. There were fewer patients who reported
adverse eEects with IV iron, but the result did not achieve
significance. There was considerable heterogeneity of results
(Analysis 3.1 (12 studies, 1488 patients: RD -0.09, 95% CI -0.19 to
0.00; I2 = 85%).
Allergic reactions and hypotension were slightly but significantly
increased with IV iron (Analysis 3.2.1 (8 studies, 1199 patients):
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RD 0.02; 95% CI -0.00 to 0.04). All gastrointestinal adverse eEects
combined (Analysis 3.2.2 (8 studies, 925 patients): RD -0.17, 95% CI
-0.27 to -0.06); and constipation, diarrhoea, and nausea or vomiting
considered individually; were significantly more common with oral
iron compared with IV iron (Analysis 3.2.3, Analysis 3.2.4, Analysis
3.2.5). There was significant heterogeneity in these results. Reports
of taste disturbance (three studies), iron overload (two studies), and
cessation of iron therapy due to adverse eEects (one study) were
analysed. No significant diEerences in heterogeneity were found in
these analyses (Analysis 3.2.6, Analysis 3.2.7, Analysis 3.2.8).
Outcomes sought but not reported
No studies reported on cardiovascular morbidity, hospitalisation,
exercise tolerance, leN ventricular function, nutritional status,
malignancy, risk of infection, cost of hospitalisation and
professional supervision required for administration of IV iron
supplement, or detailed information on CRP, or other inflammatory
markers.
D I S C U S S I O N
Summary of main results
We identified 28 studies that compared intravenous (IV) iron with
oral iron therapy in patients with CKD. There was considerable
variability among studies in dose and duration of IV and oral iron
therapies prescribed. Durations of studies ranged from 1.3 to 24
months. The doses/month of IV iron and oral iron ranged from 200
mg to1000 mg (IV); and 2898 mg to 10,500 mg (oral). Use of ESAs also
varied. Eight studies reported that ESAs were not administered.
Of the studies that reported ESA use, some maintained ESA doses
unchanged and others altered the dose to maintain haemoglobin
within a target range.
Compared with oral iron, IV iron significantly increased levels of
haemoglobin, serum ferritin and TSAT in all patients. The final
weighted mean increase in haemoglobin was 0.90 g/dL in patients
who received IV iron compared with those who received oral iron
(22 studies; 1862 patients). The proportion of patients who reached
the targeted haemoglobin or increased their haemoglobin by 1 g/
dL was 70% higher among those treated with IV iron. The weighted
mean increase in final ferritin levels (24 studies; 1751 patients)
and TSAT levels (18 studies; 1457 patients) were 243 μg/L and
10% higher respectively in patients treated with IV iron compared
with oral iron. The required ESA dose was significantly reduced
in patients treated with IV iron compared with oral iron, but was
reported in a smaller proportion of included studies (9 studies, 487
patients).
Examination of patient-centred outcomes including mortality (five
studies), cardiovascular mortality (two studies) and quality of life
(two studies) showed no significant diEerences between IV and oral
iron treated groups.
Subgroup analyses of response to treatment revealed significant
heterogeneity in haemoglobin, ferritin and transferrin levels.
Although there was no diEerence in haemoglobin MD when
IV iron dose/month was increased, haemoglobin MD increased
significantly when oral iron dose/month was reduced. However,
this significance was eliminated when a study with a high MD (4.92)
was excluded from the sensitivity analysis (Fudin 1998 HD).
Studies that were sponsored by pharmaceutical companies
were associated with a significantly greater increase in MD
in haemoglobin compared with studies that did not report
sponsorship. Ferritin levels increased significantly in terms of total
IV iron dose, but this eEect was not apparent with IV iron dose/
month. Heterogeneity among studies therefore remains largely
unexplained, but was likely to be related to the significant variation
in the relative doses of IV and oral iron used in each study.
Adverse eEects were reported in 13 studies. Overall, adverse
eEects were reported less oNen in relation to IV iron therapy.
Gastrointestinal adverse eEects were more common with oral iron,
but allergic reactions and hypotension were seen only with IV iron.
Overall completeness and applicability of evidence
Most included studies reported on laboratory assessments of
response to IV and oral iron treatment in patients with CKD
stages 3 to 5 including those receiving dialysis. Our meta-analyses
identified small but significant increases in laboratory parameters
of haemoglobin, ferritin and transferrin in both dialysis and non-
dialysis patients. Because key patient-centred outcomes were
reported in only a few studies, we were unable to make definitive
conclusions about the influence of IV iron therapy on all-cause
mortality, cardiovascular mortality and morbidity, or quality of life.
However, gastrointestinal disorders were found to be significantly
more common in patients taking oral iron. In patients with
gastrointestinal disturbances, the amount of oral iron that can be
tolerated is limited, but we found no reports that any patients
withdrew from studies because of oral iron intolerance. Although
ESA dose was significantly lower in patients treated with IV iron,
only a third of the included studies (all in dialysis patients) reported
on ESA dosage at the end of the study.
The observed haemoglobin increase of 1.16 g/dL in dialysis
patients, together with a significant reduction in ESA dose, provides
some support for the current practice of administering IV iron to
these patients, particularly among those unable to tolerate oral
iron. Further data on these and other patient-centred outcomes are
required to determine if the use of IV iron is justified.
The haemoglobin increase in non-dialysis patients was modest
(0.45 g/dL), but this was not significantly diEerent from the
response in dialysis patients. None of the included studies assessed
if the patient-centred benefits of achieving higher haemoglobin
levels outweighed financial costs or disruption to patients not on
dialysis as a result of additional or prolonged hospital visits. Only
Agarwal 2006 CKD identified some improvement in quality of life in
non-dialysis patients receiving IV iron, however the only other study
that assessed quality of life did not report any diEerences (Van Wyck
2005 CKD). There were no data relating to non-dialysis patients to
determine if ESA requirements were reduced. We were therefore
unable to derive a definitive conclusion on the relative benefits and
harms of IV iron for non-dialysis patients.
The applicability of the conclusions in children, PD patients and
kidney transplant patients may be limited since only a single small
study was identified for each of these patient groups. However the
magnitude and direction of results in these studies did not diEer
from the overall results.
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Quality of the evidence
Our review included 28 studies that involved 2098 participants,
of whom about half were on dialysis. We included one paediatric
study of 36 children on HD; one study of 46 adults on PD; and one
study of 12 kidney transplant recipients. There was considerable
variation among studies in dose and duration of IV and oral iron
administration.
Of the 28 included studies, 10 were available only as abstracts;
12 reported adequate sequence generation; and six demonstrated
adequate allocation concealment. Allocation concealment was
therefore unclear or inadequate in most studies. Studies that lack
adequate allocation concealment are considered to be at increased
risk of bias (Moyer 1998; Schultz 1995). Blinding methodology was
not reported in any study, but because key data were reported as
laboratory measurements, studies were considered to be at low
risk of bias for the primary outcomes. We found that 12 studies
provided complete data reporting, and 13 reported all outcomes.
The authors of 12 included studies indicated receiving some form
of sponsorship from pharmaceutical companies. In this review, we
observed a diEerence between studies that were sponsored by
pharmaceutical companies and those that were not. A significantly
smaller increase in haemoglobin level among patients who
received IV iron, compared with oral iron, was observed in pharma-
sponsored studies compared with the studies that did not report
pharma sponsorship. Of the 12 pharma-sponsored studies, five
demonstrated adequate allocation concealment, but only one of
the 16 remaining non-pharma sponsored studies was able to meet
this requirement. A possible explanation for this observation is that
sponsorship enabled better study design and reporting standards
to be incorporated.
Although administration of IV iron consistently resulted in an
increase in haemoglobin or haematocrit, ferritin and TSAT, there
was considerable heterogeneity among studies in the results of
these laboratory outcomes. This eEect could not be explained aNer
examining for interactions related to participants, interventions
and risk of bias items as reported.
The overall quality of included studies, and the heterogeneity in
study results, decreased the quality of evidence to moderate for the
outcomes of mean changes in haemoglobin, ferritin and TSAT and
the number achieving target haemoglobin (Summary of findings
for the main comparison). The quality of evidence for all-cause
mortality, and cardiovascular mortality, were considered to be
moderate and low respectively, because of small patient numbers
included in the studies addressing this outcome (Summary
of findings 2). The quality of evidence for end of treatment
reduction in ESA dose was considered low because of significant
heterogeneity between studies and the limited number of studies
reporting this outcome (Summary of findings 2).
Potential biases in the review process
The relatively high proportion of included studies that were
available only as abstracts (10/28) is a potential source of bias. To
address reporting gaps in studies available only as abstracts, we
contacted authors to seek additional information. Responses from
nine study authors principally related to risk of bias attributes.
Since the protocol for this review was published, the literature
search has been run several times (up to February 2010), to
reduce the likelihood that studies published before that time that
were eligible for inclusion were missed. Although the Cochrane
Renal Group's trials register includes references of reports of
studies identified by handsearching resources including conference
proceedings, it is a possibility that relevant studies may have been
added since our last search of the Register. Potentially relevant
studies were also identified from other trials registries, but at
the time of writing, data from these completed studies have
yet to be published, including a completed study (NCT00255437
on ferumoxytol) which has been reported only in abstracts that
present the combined data from several studies on this agent.
Some outcomes were reported in only a few studies which
increased the risk of selection bias. In particular, the final or change
in ESA dose was reported in nine studies (487 patients) so that
the observed significant decrease in ESA dose with IV iron therapy
compared with oral iron may not be generalisable to the dialysis
population. Similarly, adverse eEects were reported in only about
half of the included studies.
Agreements and disagreements with other studies or
reviews
A systematic review published in 2008 that included 13 studies
applied a comprehensive literature review strategy that included
searching some conference proceedings (American Society of
Nephrology, European Renal Association - European Dialysis and
Transplant Association) (Rozen-Zvi 2008). Our review included
12/13 studies included by Rozen-Zvi 2008, as well as two studies
that had been published in the interim. We excluded one study that
was included in the 2008 systematic review because it included
both randomised and non-randomised data (Allegra 1991). Rozen-
Zvi 2008 meta-analysed seven studies of dialysis patients and
six of non-dialysis patients; we compared 12 and 8 studies in
our respective meta-analyses. Both reviews reported increases in
mean haemoglobin, ferritin, TSAT and reduction in ESA dose in
patients treated with IV iron compared with oral iron. The meta-
regression analysis conducted by Rozen-Zvi 2008 demonstrated a
significant correlation between SMDs in haemoglobin and IV iron
dose/month in dialysis patients, but this was not the case in non-
dialysis patients. In this review we were unable to demonstrate an
overall correlation, or a correlation n dialysis patients alone. Both
reviews reported considerable heterogeneity for the outcomes of
haemoglobin, ferritin and TSAT concentrations which could not be
explained.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This systematic review identified evidence to indicate that
compared with oral iron therapy, IV iron therapy contributed
increased ferritin and TSAT levels, reduced ESA dose required, and
provided a small but significant increase in haemoglobin. Limited
patient-centred outcomes data (mortality, cardiovascular disease,
quality of life) were reported in the included studies. These data
support the current practice of administering IV iron to in-centre HD
patients to increase iron stores, and probably, reduce both the ESA
dose required, and its cost.
However, the included studies did not provide suEicient
evidence on patient-centred outcomes, including adverse eEects,
to determine if benefits exceed harms for all patients with
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CKD. Gastrointestinal adverse eEects were common, and oNen
debilitating, with oral iron. These eEects must be balanced against
the rare, but potentially life threatening adverse eEects that are
associated with IV iron. Further studies are required to determine
if the benefits of IV iron for non-dialysis and PD patients outweigh
the disadvantages of increased numbers and durations of hospital
visits for treatment.
Implications for research
Further large randomised studies with longer follow-up periods are
required. These need to assess patient-centred outcomes including
all-cause mortality, cardiovascular mortality, cardiac morbidity
using cardiac function tests, hospitalisations, kidney function and
time to start dialysis, quality of life and patient inconvenience
created by hospital or clinic visits for IV iron in non-dialysis or PD
patients as well as common haematological parameters. The costs
of all aspects of IV therapy must also be determined to assess
overall value of IV iron, especially in non-dialysis and PD patients.
These studies should be large enough to enable subgroup analyses
to determine which patients would benefit from IV iron, particularly
in non-dialysis patients. The doses of oral and IV iron should be
standardised across studies in an eEort to reduce the heterogeneity
seen in this systematic review.
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Characteristics of included studies [ordered by study ID]
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: 26 tertiary centres• Country: USA• Health status: GFR 10 to 59; Hb < 12 g/dL; ferritin <100 ng/mL; TSAT < 20%, no need for dialysis for ≥
16 weeks, negative stool occult blood, pregnancy test• Number: IV iron 80 (44 analysed for safety; 36 analysed for efficacy); oral iron 84 (45 analysed for safety;
39 analysed for efficacy)• Mean age ± SD: IV iron 65.5 ± 12.9 years; oral iron 62.3 ± 15.2 years• Sex (M/F): IV iron 20/16; oral iron 15/24
Exclusion criteria
• Receiving ESA or IV iron within previous 4 weeks; ferritin > 300 ng/mL; TSAT > 30%, albumin < 3 g/dL;
allergy to SFGC; anaemia due to other causes than iron deficiency; systemic infection; uncontrolled
hypertension; dialysis; kidney transplant; malignancy; clinical instability
Interventions IV iron
• Sodium ferric gluconate complex• Dose, duration, frequency: 250 mg, 4 times/week* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate
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• Dose, duration, frequency: 325 mg, 3 times/day for 6 weeks* Total dose of elemental iron: 12,285 mg
Co-intervention
• NS
Outcomes • Change in Hb at day 43• Change in TSAT at day 43• Change in ferritin at day 43• Change in CHr at day 43• Change from baseline quality of life• Adverse effects
Notes • Funding source: Watson Laboratories Inc• Follow-up period: 70 days• Loss to follow-up: 7 in IV group (16%), 8 in oral group (18%)• 8 (18%) excluded from analysis in IV group due to lack of pre-study evaluation• 6 (13%) excluded from analysis in oral group due to missing results• Exclusions post-randomisation but pre-intervention: NS• Stop or end point/s: None reported• Additional data requested from authors: Further information on methods and more detailed results
were obtained from the sponsor, Watson Laboratories Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation of blocks of 4
Allocation concealment
(selection bias)
Low risk Central randomisation
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced in both groups, reason for missing data unlikely to be
related to true outcome
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the pre-specified outcomes report-
ed
Other bias High risk Watson Laboratories Inc
Agarwal 2006 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre
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• Country: India• Health status: CKD on conservative treatment, Hb 5 to 8 g/dL, Hct 15% to 24%, negative stool occult
blood, negative direct Coombs test• Number: IV iron (20); oral iron (20)• Age range: 21 to 66 years• Sex (M/F): IV iron 13/7; oral iron 16/4
Exclusion criteria
• Age < 15 years; anaemia due to other causes; uncontrolled hypertension; CAD, chronic infections/in-
flammation; pregnancy; receiving androgen therapy during the previous month
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 100 mg; twice/month for 3 months* Total dose of elemental iron: 600 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 200 mg, 3 times/day for 3 months* Total of dose of elemental iron: 16,200 mg
Co-intervention
• EPO 2000 IU twice/week for 3 months, stable dose
Outcomes • Hb at end of study (3 months)• Ferritin at end of study (3 months)• TSAT at end of study (3 months)• PCV at end of study (3 months)• Reticulocyte % at end of study (3 months)• GFR at end of study (3 months)• Number with sensitivity reactions
Notes • Funding source: NS• Follow-up period: 3 months• Loss to follow-up: NS• Exclusions post-randomisation but pre-intervention: None reported• Stop or end point/s: None reported• Additional data requested from authors: Method of randomisation and allocation concealment re-
quested. No additional information provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Aggarwal 2003 CKD  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All reported patients included in follow up, but unclear whether any patients
included were initially excluded from analysis
Selective reporting (re-
porting bias)
High risk Some outcomes, such as symptoms of fatigue and shortness of breath, were
reported incompletely and could not be included in the meta-analysis
Other bias Unclear risk Funding source NS
Aggarwal 2003 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: USA• Health status: Adult kidney transplant recipients; Hct < 35 %; TSAT < 25 % at day 5 post transplant• Number: IV iron (6); oral iron (6)• Age: IV iron 45.8± 4.7 years (SD); oral iron 46.6± 8.1 years (SD)• Sex (M/F): IV iron 5/1; oral iron 4/2
Exclusion criteria
• Delayed graN function requiring dialysis, received blood transfusion, acute rejection
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 1000 mg single dose* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg; 3 times/day for 3 months* Total dose of elemental iron: 26,325 mg
Outcomes • Hct at end of study• TSAT at end of study• Cr at end of study
Notes • Abstract only• Funding source: NS• Follow-up period: 8 weeks• Loss to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We requested data on method of randomisation and alloca-
tion concealment, excluded patients before randomisation, and side effects. No additional informa-
tion was obtained
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Scant data available from abstract
Selective reporting (re-
porting bias)
Unclear risk Limited information to judge
Other bias Unclear risk Funding source NS
Ahsan 1997 TX  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: Iran• Health status: Patients on HD, EPO for 6 months• Number: IV iron (9); oral iron (8)• Age: NS• Sex: NS
Exclusion criteria
• Evidence of active and chronic infection
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 100 mg twice/week for 6 months* Total dose of elemental iron: 4800 mg
Oral iron
• Ferrous formate• Dose, duration, frequency: 350 mg for 6 months* Total oral elemental iron: 63,000 mg
Co-intervention
• EPO 2000 IU three times/week 6 months prior to study, stable dose
Outcomes • Hb, Hct and ferritin at end of study (6 months)
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Notes • Abstract only• Funding source: NS• Randomisation method: NS• Follow-up period: 6 months• Loss to follow-up: NS, started with 20 patients, 3 excluded before randomisation due to HCV positivity,
hypertension while on EPO• Exclusions post randomisation but pre-intervention: None reported• Stop or end points: None reported• Additional data requested from authors: We contacted authors seeking information on the method
of randomisation and allocation concealment, type of oral iron, number of patients in both groups,
whether SD or SE were reported, and data on ferritin. The authors provided data on type of oral iron,
ferritin data, and patient numbers
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were included in analysis
Selective reporting (re-
porting bias)
High risk Limited information on methods. SDs imputed
Other bias Unclear risk Funding source NS
Broumand 1998 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: Adult > 18 years; not on dialysis;, CrCl <  40 mL/min; Hb < 10.5 g/dL; TSAT < 25 %; ferritin
< 300 ng/mL; absence of other causes of anaemia; absence of infection, surgery and cancer; expected
survival > 6 months• Number: IV iron (48; 39 analysed for efficacy and safety); oral iron (48; 44 analysed for efficacy and
safety)• Mean age ± SD: IV iron 62 ± 14.4 years; oral iron 60 ± 14.4 years• Sex (M/F): IV iron 19/29; oral iron 14/34
Exclusion criteria
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• IV iron or ESA within past month; blood transfusion within past month; gastrointestinal bleeding; al-
bumin < 3 g/dL; pregnancy or lactation; HIV positivity; expected to commence dialysis or kidney trans-
plant
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 200 mg weekly for 5 weeks* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate (elemental iron 195 mg/d)• Dose, duration, frequency: 325 mg 3 times/day for 29 days* Total dose of elemental iron: 5655 mg
Co-intervention
• EPO 2000 IU/week for 6 weeks, stable dose, started at day 1 of study
Outcomes • Final Hb and change in Hb at day 43• Change in TSAT at day 43• Change in ferritin at day 43• Number with adverse effects• Number reaching Hb > 11 g/dL
Notes • Funding source: American Regent Inc• Follow-up period: 43 days• Loss to follow-up: NS. 39/48 in IV group completed. 44/48 in oral group completed• Exclusions post randomisation but pre-intervention: Unclear• Stop or end points: None reported• Additional data requested from authors: We contacted authors seeking information on method of ran-
domisation and allocation concealment, SD for continuous variables, denominator for dichotomous
outcomes as only percentages. No information was obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Reasons for patients not completing the trial were not provided, patients with
missing data were excluded from analysis (19% missing in IV, 8% missing in
oral group). Data were provided as percentages with unclear denominators
Selective reporting (re-
porting bias)
High risk Data were not provided with SD. SD imputed to enable entry in meta-analyses
Other bias High risk Funded by American Regent Inc
Charytan 2005 CKD  (Continued)
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Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: Turkey• Health status: Hb < 10 g/dL; HD; hyporesponsiveness to ESA for at least 3 months; no other causes of
ESA resistance• Number: IV iron group 1 (26), IV iron group 2 (21); oral iron (22)• Age: NS• Sex (M/F): NS
Exclusion criteria
• NS
Interventions IV iron group 1
• Iron sucrose• Dose, duration, frequency: 100 mg/session for 10 sessions then 100 mg/week for 6 months* Total dose of elemental iron: 3400 mg• Data from this group used in meta-analyses
IV iron group 2
• Iron sucrose• Dose, duration, frequency: 100 mg for 10 sessions for 6 months* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 200 mg/day for 6 months* Total dose of elemental iron: 10,800 mg
Co-intervention
• EPO 150 IU/kg 3 times/week for at least 3 months before study, dose varied during study
Outcomes • Hb at end of study (6 months)• Ferritin at end of study (6 months)• Change in EPO dose
Notes • Abstract only• Funding source: NS• Follow-up period: 6 months• Loss to follow-up: NS, 1 patient excluded from IV group due to side effects• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors seeking information concerning
method of randomisation and allocation concealment requested. No additional data were obtained
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Hematological outcomes not affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only one patient excluded from analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
Other bias Unclear risk Funding source NS
Erten 1998 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/ time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: USA• Health status: HD for at least 3 months; receiving ESA and oral iron for 3 months; no recent bleeding
or transfusion; no haematologic disease other than anaemia; not treated with IV iron for at least 6
months; ferritin >100 ng/mL, TSAT> 15%• Number: IV group (20), oral group (32)• Mean age ± SD: IV group (48.7± 8.7 years); oral group (50.2 ± 9.9 years)• Sex (M/F):IV group (13/7); oral group (18/14)
Exclusions
• NS
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 100 mg twice/week for 4 months* Total dose of IV iron: 3200 mg
Oral iron
• Ferrous sulphate (21/32)* Dose, duration: 325 mg three times/day for 4 months* Total dose of elemental iron: 35,100 mg• Iron polysaccharide (11/32)* Dose, duration, frequency: 150 mg twice/day for 4 months
Co-intervention
Fishbane 1995 HD 
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• ESA started at least 3 months before study, dose adjusted to maintain Hct 30% to 34%
Outcomes • Hct, Hb at end of study• TSAT at end of study• Ferritin at end of study• EPO dose at end of study• Number with reduction in ESA• Number with side effects
Notes • Funding source: NS• Follow-up period: 4 months• Loss to follow-up: 5/25 discontinued treatment in IV group (one from diarrhoea, 2 from other illnesses,
2 from bleeding); 18/50 discontinued treatment in the oral group (4 failed treatment, others due to
illness, bleeding, death)• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek information concerning
method of randomisation and allocation concealment. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Large number excluded from analysis, 20% in oral group, 36% in IV group
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the pre-specified outcomes report-
ed
Other bias Unclear risk Funding source NS
Fishbane 1995 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: Israel• Health status: No blood transfusion or iron during previous year; commencing HD; no malignancy or
chronic inflammation; no severe hyperparathyroidism; no other causes of anaemia• Number: IV iron (24); oral iron (12)• Mean age ± SD: IV iron (56.6 ± 15.1 years); oral iron (42.6 ± 17.03 years)
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• Sex (M/F): IV iron (12/8); oral iron (5/5)
Exclusion criteria
• NS
Interventions IV iron
• Iron sodium gluconate complex• Dose, duration, frequency: 62.5 mg/week until TSAT 35%, then 62.5 mg or 125 mg/month to maintain
TSAT* Total dose of elemental iron could be calculated
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 150 mg ferrous sulphate equivalent to 50 mg/day of elemental iron* Total dose of elemental iron: 39,000 mg
Co-intervention
• NS
Outcomes • Hb at end of study (26 months)• Ferritin at end of study (26 months)• TSAT at end of study (26 months)
Notes • Funding source: NS• Follow-up period: 26 months• Loss to follow-up: 4/24 (16%) in the IV group were excluded from analysis, 2/12 (16%) in the oral iron
were excluded from analysis• Exclusions post randomisation but pre-intervention: NS• The authors included a third group of 9 patients who were not treated with iron supplements so not
included in the analysis• Stop of end points: NS• Additional data requested from authors: We contacted authors to seek information concerning final
Hb and TSAT. Data were provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of 1000 random digits generated by multiplicative congruent method
Allocation concealment
(selection bias)
High risk Open random allocation schedule
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 16% in both groups did not complete and were excluded from the analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
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Other bias Unclear risk Funding source NS
Fudin 1998 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: Pakistan• Health status: Hb <8.5 g/dL; ferritin 200 to 800 ng/mL; TSAT> 30%, on HD; normal vitamin B12, folate• Number: IV iron (10); oral iron (10)• Age: IV iron (58.4 years); oral iron (56 years)• Sex (M/F): IV iron (6/4); oral iron (5/5)
Exclusion criteria
• Uncontrolled hypertension; severe hyperparathyroidism; active peptic ulcer disease; hypersensitivity
to IV iron
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 100 mg twice/week for 3 months* Total dose of elemental iron: 2400 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 200 mg 3 times/day for 3 months* Total dose of elemental iron: 16,200 mg
Co-intervention
• EPO 25 U/kg/week twice weekly, dose altered during study
Outcomes • Hb at end of study (3 months)• Ferritin at end of study (3 months)• TSAT at end of study( 3 months)• Mean EPO dose/week at end of study (3 months)• Number with change in EPO dose
Notes • Funding source: NS• Follow-up period: 3 months• Lost to follow-up: NS• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek information concerning
method of randomisation and allocation concealment. No additional data were not obtained
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether results of all patients were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Limited information on methods
Other bias Unclear risk Funding source NS
Hussain 1998 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: USA• Health status: HD > 6 months; no IV iron for 6 months; no recent bleeding or blood transfusion; on ESA
> 3 months; Hct > 30%; ferritin > 100 ng/mL; TSAT> 20%• Number: IV iron (18, 15 analysed); oral iron (19, 16 analysed)• Age: NS• Sex (M/F): NS
Exclusion criteria
• Positive for HIV, other haematological disorders
Interventions IV iron
• Iron (preparation NS)• Dose, duration, frequency: 100 mg/week for 5 months* Total dose of elemental iron: 2000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg, 3 times/day for 5 months* Total dose of elemental iron: 43,875 mg
Co-intervention
• ESA > 3 months before study, dose varied
Outcomes • Hb at end of study (5 months)• Ferritin at end of study (5 months)• TSAT at end of study (5 months)
Kotaki 1997 HD 
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• Mean ESA dose at end of study (5 months)
Notes • Funding source: NS• Follow-up period: 5 months• Lost to follow-up: 3/18 (17%) from IV group; 3/19 (16%) from oral group• Exclusion post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek additional information con-
cerning method of randomisation and allocation concealment. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced across groups
Selective reporting (re-
porting bias)
Low risk Prespecified outcomes were reported
Other bias Unclear risk Funding source NS
Kotaki 1997 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame:NS
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: CKD stages 3 to 5 not on dialysis; Hb < 12 g/dL; ferritin < 100 ng/mL and/or TSAT < 20%;
stable ESA dose for > 4 weeks before enrolment• Number: IV iron (26 safety arm, 24 efficacy arm); oral iron (24 safety arm, 24 efficacy arm)• Age: NS• Sex (M/F): NS
Exclusion criteria
• Dialysis patients; positive FOBT result
Interventions IV iron
• Sodium ferric gluconate complex
Leehey 2005 CKD 
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• Dose, duration, frequency: 250 mg/week for 4 weeks* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg, 3 times/day for 6 weeks* Total dose of elemental iron: 12,285 mg
Co-intervention
• EPO: ≥ 4000 IU/week or ≥ 20 μg/week (darbepoetin), stable dose
Outcomes • Hb at end of study (10 weeks)• Ferritin at end of study (10 weeks)
Notes • Abstract only• Funding source: Watson Laboratories Inc• Follow-up period: 10 weeks• Lost to follow-up: Unclear• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek additional information con-
cerning SDs and numbers completing the study. The sponsor provided additional data on the study
design, but no data on results
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation schedule
Allocation concealment
(selection bias)
Low risk Central randomisation in blocks of 4 at a 1:1 ratio. Investigators had no prior
knowledge of allocation
Blinding (performance
bias and detection bias)
Low risk Laboratory based outcome unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only
Selective reporting (re-
porting bias)
High risk Abstract only. Reported change in haemoglobin and ferritin. No SDs provided.
SD imputed for inclusion in meta-analyses
Other bias High risk Funded by Watson Laboratories Inc
Leehey 2005 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre
Li 2008 HD 
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• Country: China• Health status: Stable on HD for 1 month, ferritin < 500 ng/mL, TSAT < 30%, Hb 60 to 90 g/dL, Hct 18 to
24%, all on oral iron and ESA pre-study• Number: IV iron (70); oral iron (66)• Mean age ± SE: IV iron (53.6 ± 13.8); oral iron (54.9 ± 12.6)• Sex (M/F): IV iron (31/39); oral iron (26/40)
Exclusion criteria
• Severe liver disease; hypersplenism; haemorrhage; blood transfusion in previous month; malignancy,
sensitive to iron; high CRP > 20 mg/L; severe infection or inflammation
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 100 mg twice/week for 8 weeks, then once/week for 4 weeks* Total dose of elemental iron: 2000 mg
Oral iron
• Ferrous succinate• Dose, duration, frequency, administration: 200 mg 3 times/day for 12 weeks* Total dose of elemental iron: 16,800 mg
Co-intervention
• EPO 100 to 150 IU/kg/week started before study, dose varied; folic acid; vitamin B12
Outcomes • Final or change in Hb (12 weeks)• Final ferritin (12 weeks)• Final TSAT (12 weeks)• Mean ESA dose at end of study (12 weeks)• Number with adverse effects• Number with a specific rise in Hb
Notes • Funding source: NS• Follow-up period: 12 weeks• Lost to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek additional information con-
cerning method of randomisation and allocation concealment, and whether data were expressed as
SD or SE. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised random number list
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Haematological outcomes unlikely to be affected by lack of blinding
Li 2008 HD  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data. All participants completed the study and were included in the
analysis
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes were reported
Other bias Unclear risk Funding source NS
Li 2008 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: China• Health status: Stable on PD for 1 month; ferritin < 500 ng/mL; TSAT < 30%; Hb 60 to 90 g/L; Hct 18%
to 27%• Number: IV iron (26); oral iron (20)• Mean age ± SE: IV iron (56.9 ± 14.8); oral iron (57.6 ± 15.6)• Sex (M/F): IV iron (12/14); oral iron (9/110
Exclusion criteria
• Severe liver disease; hypersplenism; haemorrhage; active gastrointestinal ulcer; blood transfusion in
previous month; malignancy; sensitive to iron; high CRP > 20 mg/L; severe infection or inflammation;
malnourished
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 200 mg/week for 4 weeks, then every second week for 8 weeks* Total dose of elemental iron: 1200 mg
Oral iron
• Ferrous succinate• Dose, duration, frequency: 200 mg, 3 times/day for 8 weeks* Total dose of elemental iron: 11,200 mg
Co-intervention
• ESA 100 to 150 U/kg/week before study, dose varied during study
Outcomes • Final or change in Hb (8 weeks)• Final or change in ferritin (8 weeks)• Final or change in TSAT (8 weeks)• Mean ESA dose at end of study (8 weeks)• Cr at end of study• Number with adverse effects• Number with specific rise in Hb
Notes • Funding source: NS
Li 2008 PD 
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• Follow-up period: 8 weeks• Lost to follow-up: NS• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek additional information con-
cerning Method of randomisation and allocation concealment, and whether data were expressed as
SE or SD. No additional data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer random number list
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing data
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes were reported
Other bias Unclear risk Funding source NS
Li 2008 PD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: Singapore• Health status: Stable on HD ≥ 3 months; ferritin ≥ 100 ng/mL; TSAT ≥ 20%; no ESA for ≥ 1 month; ade-
quate B12 and folate levels; no sepsis; no chronic inflammation; no active bleeding• Number: IV iron (30); oral iron (30)• Age: NS• Sex (M/F): NS
Exclusion criteria
• Bleeding, severe infection or inflammation
Interventions IV iron
• Ferric hydroxide polymaltose complex (Ferrum)• Dose, duration, frequency: 200 mg/month for 24 weeks* Total dose of elemental iron: 1200 mg
Lye 2000 HD 
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Oral iron
• Ferrous fumarate• Dose, duration, frequency: 200 mg 3 times/day for 24 weeks* Total dose of elemental iron: 33,600 mg
Co-intervention
• EPO 4000 U/week started at study commencement. Dose stable through study
Outcomes • Hb at end of study (24 weeks)• Ferritin at end of study (24 weeks)
Notes • Abstract only• Funding source: NS• Follow-up period: 24 weeks• Lost to follow-up: Unclear• Exclusions at post randomisation: NS• Stop or end points: NS• Additional data requested from authors: The author provided information on numbers in each group
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract only. No information provided
Allocation concealment
(selection bias)
High risk Inadequate allocation. Author reported that patients were allocated alternate-
ly to each group
Blinding (performance
bias and detection bias)
Low risk Abstract only. Outcome was laboratory based and unlikely to be influenced by
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only. No information provided
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Reported end of study Hb and ferritin levels. Patient numbers
provided by the author
Other bias Unclear risk Abstract only
Lye 2000 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: UK• Health status: Stable on HD or CAPD > 3 months; CKD stage 5; Hb ≤ 8.5 g/dL on 3 occasions; normal
folate and vitamin B12 levels; ferritin 100 to 800 μg/L; no other cause of anaemia; no malignancy; nor-
mal CRP; no infection; no surgery in last 3 months; no hyperparathyroidism
Macdougall 1996 HD,PD,CKD 
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• Number: IV iron (13, 1 discontinued due to anaphylactoid reaction; 12 were analysed); oral iron (13)• Mean age ± SD: IV iron (47 ± 15); oral iron (58 ± 16)• Sex (M/F): IV iron (6/6); oral iron (8/5)
Exclusion criteria
• Severe hyperparathyroidism (PTH > 100 pmol/L); uncontrolled hypertension; aluminium toxicity
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 250 mg every 2 weeks for 16 weeks* Total dose of elemental iron: 2000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 200 mg three times/day for 16 weeks* Total dose of elemental iron: 21,600 mg
Outcomes • Hb at end of study (16 weeks)• Ferritin at end of study (16 weeks)• TSAT at end of study (16 weeks)• Mean ESA dose at end of study (16 weeks)• Number with a change in ESA dose
Notes • Funding source: NS• Follow-up period: 16 weeks• Lost to follow-up: none• Exclusions post randomisation and pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: Further details concerning method of randomisation and
allocation concealment were requested. Data were provided by the authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes containing random numbers
Allocation concealment
(selection bias)
Low risk Central, by pharmacy
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk  
Selective reporting (re-
porting bias)
Low risk  
Other bias Unclear risk Funding source NS
Macdougall 1996 HD,PD,CKD  (Continued)
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Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Country: UK• Setting: Multicentre• Health status: Stable on dialysis; receiving ESA; Hb 9 to 12 g/dL; ferritin 100 to 600 ng/mL• Number: IV iron (41); oral iron (35)• Age: NS• Sex (M/F): NS
Exclusion criteria
• NS
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 20 mg/dialysis session in HD patients and 200 mg/month in PD patients
for 24 weeks* Total dose of elemental iron 1200 mg in PD and 1440 mg in HD (assuming dialysis 3 times/week)
Oral iron
• No information provided
Co-intervention
• Dose of ESA varied during study according to requirements
Outcomes • Hb at end of study (24 weeks)• Ferritin at end of study (24 weeks)• ESA dose at end of study (24 weeks)• Per cent with rise in Hb > 1 g/dL (24 weeks)
Notes • Abstract only• Funding source: NS - abstract only• Follow-up period: 24 weeks• Lost to follow-up: Unclear• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: None
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract only
Allocation concealment
(selection bias)
Unclear risk Abstract only
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Blinding (performance
bias and detection bias)
Low risk Abstract only. Outcome was laboratory based and unlikely to be influenced by
blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only. Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Reported end of study Hb, ferritin and per cent of participants
who had a rise in Hb
Other bias Unclear risk Abstract only
Macdougall 1999 HD,PD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: Australia• Health status: CKD stages 3 to 5 (GFR ≤ 35 in non-diabetic participants, ≤ 50 in diabetic participants),
non-dialysis; Hb > 11 g/dL; 36% diabetic; ESA naïve; aged 18 to 80 years, clinically significant fall in Hb
and/or Cr in past 18 months• Number: IV iron (52, 43 completed at least 6 months, 39 completed 12 months); oral iron (48, 42 com-
pleted at least 6 months, 38 completed 12 months)• Median age, IQR: IV iron (70 years, 58 to 75); oral iron (68 years, 59 to 74)• Sex (M/F): IV iron (40/12); oral iron (33/15)
Exclusion criteria
• Receiving ESA; iron overload (ferritin > 300 μg/L, TSAT > 25%); severe iron deficiency (ferritin < 30,
TSAT < 15); active malignancy, bleeding or haemolysis; chronic sepsis or inflammation (CRP > 25 mg/
L); severe IHD or CHF; adult PCKD
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 100 to 200 mg every second month for 12 months to maintain ferritin 300
at 500 and/or TSAT 25% to 50%; 34 participants required monthly IV iron on one or more occasions.* Dose of elemental iron could not be calculated
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg (105 mg elemental iron) to maintain ferritin at 100 to 150 and/or
TSAT 20% to 25%; 6 participants required no iron, 25 needed iron intermittently, 5 intolerant to iron
and needed IV iron intermittently.* Dose of elemental iron could not be calculated
Co-intervention
• ACEi administered to 51/52 IV group participants and 45/48 oral group participants
Outcomes • Hb at end of study (at least 6 months) and 12 months• Ferritin at end of study (at least 6 months) and 12 months
McMahon 2009 CKD 
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• TSAT at end of study (at least 6 months) and 12 months• eGFR at end of study
Notes • Funding source: Vifor• Follow-up period: 6 months or more; maximum 12 months• Lost to follow-up: IV group (9 died or discontinued, 14%); oral group (6 died or discontinued, 12.5%)• Exclusions post randomisation: NS• Stop or end points: None• Additional data requested from authors: We contacted authors to seek additional information con-
cerning allocation concealment and data on missing patients. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple block randomisation from block randomisation lists generated with
Graphpad Statmate
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Open label study but outcomes based on laboratory results unlikely to be in-
fluenced by lack of blinding.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were accounted for. Patients not completing 6 months were ex-
cluded a priori
Selective reporting (re-
porting bias)
Low risk Primary outcomes (end Hb, ferritin, TSAT) reported in either full publication or
abstract
Other bias High risk Grant/research support from Vifor (NCT 000202345)
McMahon 2009 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Tertiary centre• Country: USA• Health status: Adult HD patients; iron replete; stable ESA dose for 8 weeks; TSAT 20% to 50%; ferritin
100 to 800 ng/mL• Number: IV iron (33); oral iron (27)• Age: NS• Sex (M/F): NS
Exclusion criteria
• NS
Interventions IV iron
• Sodium ferric gluconate complex
Michael 2007 HD 
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• Dose, duration, frequency: 62.5 mg/week for 20 weeks* Total dose of elemental iron: 1250 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg, 3 times/day for 20 weeks* Total dose of elemental iron: 40,950 mg
Co-intervention
• ESA started before the study. Dose varied during study
Outcomes • Change in Hb• Change in ferritin• Change in TSAT• Change in ESA dose
Notes • Abstract only• Funding source: Watson Laboratories• Follow-up period: 22 weeks• Lost to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We sought method of randomisation and allocation conceal-
ment from authors. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not mentioned
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk No clear protocol
Other bias High risk Grant/Research support: Watson Laboratories
Michael 2007 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: October 2005 to April 2007
Participants Inclusion criteria
Provenzano 2009 HD 
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• Setting: Multicentre• Country: USA• Health status: Adults aged > 18 years; on HD for ≥ 90 days; Hb <11.5 g/dL; TSAT < 30%; ferritin < 600
ng/mL; stable ESA (dose ± 25 %) for ≥10 days before study commencement• Number: IV iron (114; 110 started, 102 completed); oral iron (116; 114 started, 99 completed)• Mean age ± SD: IV iron (59.5 ± 14.3); oral iron (60.8 ± 13)• Sex (M/F): IV iron (57/57); oral iron (73/43)
Exclusion criteria
• Pregnancy or breastfeeding; other causes of anaemia; use of investigational drug within 30 days; iron
treatment within 10 days; recent blood transfusion; active infection; allergy to iron or drug classes
Interventions IV iron
• Ferumoxytol• Dose, duration, frequency: 510 mg for 2 doses* Total dose of elemental iron: 1020 mg
Oral iron
• Ferrous fumarate• Dose, duration, frequency: 200 mg/day for 21 days* Total dose of elemental iron: 4200 mg
Co-intervention
• ESA maintained stable
Outcomes • Final Hb and change in Hb (35 days)• Final ferritin and change in ferritin (35 days)• Final TSAT and change in TSAT (35 days)• Change TIBC, CHr at end (35 days)• Number with adverse events• Per cent who had a specific rise in Hb > 1 g/dL
Notes • Funding source: AMAG Pharmaceuticals• Follow-up period: 35 days• Lost to follow-up: 8 withdrew from IV group, 4 due to adverse effects (7%), 15 withdrew from oral
group, 9 due to adverse effects (13%)• Exclusions post randomisation but pre-intervention: IV group (4); oral group (2)• Stop or end points: NS• Additional data requested from authors: We sought additional information about method of randomi-
sation and allocation concealment from authors. Some data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Low risk Telephone-based system
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Provenzano 2009 HD  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients who were randomised were included in the analysis
Selective reporting (re-
porting bias)
Low risk All outcomes defined in study registration reported
Other bias High risk Funded by AMAG Pharmaceuticals whose employees identified study sites,
monitored the study and performed data analyses according to a predefined
statistical analysis plan
Provenzano 2009 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: Non-dialysis patients GFR < 45 mL/min; Hb < 11g/dL; TSAT < 25%; ferritin < 300 ng/mL• Number: IV iron (147); oral iron (103)• Age: NS• Sex (M/F): NS
Exclusion criteria
• NS
Interventions IV iron
• Ferric carboxymaltose• Dose, duration, frequency: 1000 mg with up to 2 additional doses of 500 mg* Total dose of elemental iron could not be calculated
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg 3 times/day for 56 days* Total dose of elemental iron: 16,380 mg
Co-interventions
• ESA in some patients, stable ESA dose before and during study
Outcomes • Change in Hb• Number having a rise in Hb• Number with adverse reactions
Notes • Abstract only• Funding source: American Reagent/Luipold Pharmaceuticals• Follow-up period: 56 days• Loss to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS
Qunibi 2007 CKD 
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• Additional data requested from authors: We sought information regarding method of randomisation
and allocation concealment, number analysed, SD of change in Hb. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The number of patients analysed in each group was unclear
Selective reporting (re-
porting bias)
High risk No clear protocol available. SDs imputed for inclusion in meta-analyses
Other bias High risk Funding support from American Reagent/Luipold Pharmaceuticals
Qunibi 2007 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: Brazil• Health status: HD patients considered iron deficient based on Hb and ferritin levels• Number: IV iron (12); oral iron (12)• Age: NS• Sex (M/F): NS
Exclusion criteria
• NS
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: Dose calculated based on iron status and body weight* Total dose of elemental iron could not be calculated
Oral iron
• Ferrous sulphate• Dose, duration, frequency: Dose calculated based on iron status* Total dose of elemental iron could not be calculated
Co-intervention
Souza 1997 HD 
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• Some patients received ESA
Outcomes • Change in Hb• Change in ferritin• Change in iron status
Notes • Abstract only• Funding source: NS• Follow-up period: NS• Lost to follow-up: IV group: 4 (33%) did not complete; oral group: 1 (8%) did not complete• Exclusion post randomisation but pre-intervention: NS• Stop or end point: NS• Additional data requested from authors: We sought information regarding method of randomisation
and allocation concealment, number of patients in each group, dose of oral iron, number of patients
who were on ESA, variation in the dose of ESA during study, change in haemoglobin for those who
were on ESA. No data were obtained
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear if all patients completed study
Selective reporting (re-
porting bias)
Unclear risk No clear protocol
Other bias Unclear risk Funding source NS
Souza 1997 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: May 2004 to August 2006
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: Adults on HD with CKD stages 1 to 5; Hb < 11 g/dL; TSAT < 30%; ferritin < 600 ng/mL; no
change in ESA while in study; no parenteral or oral iron within 10 days of study start• Number: IV iron (228; 217 started, 207 completed); oral iron (76; 75 started, 63 completed)• Mean age ± SD: IV iron (65.1 ± 14.3); oral iron (63.7 ± 11.6)• Sex (M/F): IV iron (93/135); oral iron (24/52)
Spinowitz 2008 CKD 
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Exclusion criteria
• Pregnancy or breastfeeding; other causes of anaemia; recent iron therapy; cancer; PTH > 1500 pg/mL;
bleeding; surgery; recent blood transfusion; active infection; allergy to IV iron
Interventions IV iron
• Ferumoxytol• Dose, duration, frequency: 510 mg, 2 doses* Total dose of elemental iron: 1020 mg
Oral iron
• Ferrous fumarate• Dose, duration, frequency: 100 mg elemental iron twice/day for 21 days* Total dose of elemental iron: 4200 mg
Co-intervention
• ESA stable dose at < 35,000 IU/week or < 120 μg darbepoetin every 2 weeks or not started. 83/228 in
IV group received ESA, 33/76 in oral group received ESA
Outcomes • Final or change in Hb (35 days)• Final or change in ferritin (35 days)• Final or change in TSAT (35 days)• Number with adverse events• Per cent with rise in Hb > 1 g/dL
Notes • Funding source: AMAG Pharmaceuticals• Follow-up period: 35 days• Lost to follow-up: IV group (10 patients did not complete study); oral group (12 patients did not com-
plete study)• Exclusion post randomisation but pre-intervention: IV group (11); oral group (1)• Stop or end points: None stated• Additional data requested from authors: We sought information regarding method of randomisation
and allocation concealment. Data were obtained from authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk 3:1 automated preprogrammed interactive voice response system
Allocation concealment
(selection bias)
Low risk Telephone based
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data of primary endpoint balanced between groups,10% IV,13% oral
Selective reporting (re-
porting bias)
Low risk Study protocol available in paper and all of the prespecified outcomes report-
ed
Spinowitz 2008 CKD  (Continued)
Parenteral versus oral iron therapy for adults and children with chronic kidney disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Other bias High risk Funded by AMAG Pharmaceuticals whose employees identified study sites,
monitored the study and performed data analyses according to a predefined
statistical analysis plan
Spinowitz 2008 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: UK• Health status: Progressive deterioration in renal function; Cr > 250 μmol/L; not on dialysis; worsening
anaemia; Hb <11 g/dL; not on ESA• Number: IV iron (22, 15 completed); oral iron (23, 17 completed)• Mean age ± SD: IV iron (57.3 ±14); oral iron (59.9 ± 13.4)• Sex (M/F): IV iron (10/12); oral iron (15/8)
Exclusion criteria
• Treatment with IV iron for previous 6 months; malignancy; intolerance to oral iron; poor compliance;
dialysis, on ESA; gastrointestinal bleeding
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 300 mg monthly according to ferritin levels* Total dose of elemental iron: 1638 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 200 mg 3 times/day for 6 months* Total dose of elemental iron: 32,400 mg
Co-intervention
• EPO 2000 IU twice weekly started at start of study, dose varied, ACEi 23% IV group, 52% oral group
Outcomes • Hb at end of study• Ferritin at end of study• ESA dose at end of study• Number with adverse events• Number reaching target Hb• Number with change in ESA dose
Notes • Funding source: Janssen Cilag and Syner-Med• Follow-up period: 6 months• Lost to follow-up: IV group: 7 (32%) discontinued; oral group 6 (26%) discontinued• Exclusion post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We sought information regarding method of allocation con-
cealment, Hb mean change and SD. No information was obtained
Stoves 2001 CKD 
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• Email from Dr Richardson (8 Jan 2011) stated that the RCT registered in Current Clinical Trials is the
report published by Stoves et al. No further information available as to why the RCT was published in
2001 but the trial registered in 2004
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer based
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 29% did not complete the study; this large number could induce bias the re-
sults
Selective reporting (re-
porting bias)
High risk Outcomes reported as median and IQR and could not be entered in meta-
analyses
Other bias High risk Imbalance between ACEi treatment in each group
Sponsored by Janssen Cilag and Syner-Med
Stoves 2001 CKD  (Continued)
 
 
Methods Study design: cross-over RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: University teaching hospital• Country: UK• Health status: HD for 3 months; no previous iron supplements• Number: IV iron 20 (19 completed 26 weeks and crossed over, 15 completed 52 weeks, 5 discontinued);
oral iron (20)• Age: NS• Sex (M/F): NS
Exclusion criteria
• Blood transfusion in the previous 3 months; low vitamin B12; folate; kidney transplant with rejection
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 100 mg every 2 weeks* Total dose of elemental iron: 1300 mg
Oral iron
• Ferrous sulphate
Strickland 1977 HD 
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• Dose, duration, frequency: 100 mg daily for 26 weeks* Total dose of elemental iron: 18,200 mg
Co-interventions
• NS
Outcomes • Hb change reported for all who received IV and oral iron• Number with adverse reactions
Notes • Funding source: Abbott Laboratories Ltd and Fisons Pharmaceuticals Ltd• Follow-up period: 52 weeks• Loss to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: Because of the date of the study (1977), authors were not
contacted
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Balanced allocation within strata using a method similar to the minimisation
procedure
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 25% of participants were excluded from analysis
Selective reporting (re-
porting bias)
High risk Data combined in crossover study and could not be incorporated in meta-
analyses
Other bias High risk Funding support from Abbott Laboratories Ltd and Fisons Pharmaceuticals Ltd
Strickland 1977 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single centre• Country: Czech Republic• Health status: HD patients; ferritin < 300 ng/mL; TSAT < 20 %; EPO 60 U/kg/week in both groups and
were on a stable dose• Number: IV iron (30, 29 analysed); oral iron (32, 28 analysed)• Mean age: IV iron (61 years); oral iron (61 years)• Sex (M/F): NS
Svara 1996 HD 
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Exclusion criteria
Non dialysis patients
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 100 mg/week for 6 weeks* Total dose of elemental iron: 600 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 34.5 mg, 3 times/day (total dose 724.5 mg/week)* Total dose of elemental iron: 4347 mg
Co-intervention
• EPO 60 IU/kg/week in both groups and were on a stable dose
Outcomes • Hb at end of study (6 weeks)• Ferritin at end of study (6 weeks)• TSAT at end of study (6 weeks)
Notes • Funding source: NS• Randomisation method: NS• Follow-up period: 6 weeks• Loss to follow-up: None; 4 patients excluded from analysis• Exclusion post randomisation but pre-intervention: IV iron: 1 excluded (chronic inflammatory
process); oral iron: 3 excluded (gastrointestinal intolerance)• Stop or end points: NS• Additional data requested from authors: None requested
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation NS
Allocation concealment
(selection bias)
Unclear risk Method of allocation NS
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Three patients were excluded from oral, one from IV group
Selective reporting (re-
porting bias)
Low risk All outcomes specified in methods were reported
Other bias Unclear risk Funding source NS
Svara 1996 HD  (Continued)
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Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: Non-dialysis patients; CKD stages 3 to 5; Hb <11 g/dL; TSAT < 25%; ferritin < 300 ng/mL;
no ESA or no change in ESA for 8 weeks; no IV iron for 6 months• Number: IV iron (95, 91 started treatment); oral iron (93, 91 started treatment)• Age: IV iron (62.3 years); oral iron (63.9 years)• Sex (M/F): IV iron (26/53); oral iron (26/56)
Exclusion criteria
• Treatment with IV iron for previous 6 months; malignancy; allergy to oral or IV iron; infection; major
surgery in the prior month; blood transfusion within 2 months; bleeding within 3 months; severe liver
disease; pregnancy; lactation; asthma; haemochromatosis
Interventions IV iron
• Iron sucrose• Dose, duration, frequency: 1000 mg, divided doses over 14 days* Total dose of elemental iron: 1000 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 325 mg, 3 times/day for 56 days* Total dose of elemental iron: 10,920 mg
Co-intervention
• ESA use in some of patients, dose stable
Outcomes • Change in Hb at end of study (56 days)• Change in ferritin at end of study (56 days)• Change in TSAT at end of the study (56 days)• Change in ESA dose• Number reaching target Hb or a specific rise• Number with adverse events
Notes • Funding source: American Regent, Inc• Follow-up period: 56 days• Lost to follow-up: IV iron: 12 (13%) participants excluded from the analysis (discontinued treatment);
oral iron: 9 (10%) excluded (discontinued treatment) due to unstable ESA dose prior to randomisation
or lack of baseline data and 2 lost to follow-up• Exclusions post randomisation but pre-intervention: IV iron = 4; oral iron = 2• Stop or end points: NS• Additional data requested from authors: We contacted author to seek method of allocation conceal-
ment and randomisation, numerical values for the change in Hb, TSAT, ferritin as mean and SD. Data
were provided by authors
Risk of bias
Bias Authors' judgement Support for judgement
Van Wyck 2005 CKD 
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Random sequence genera-
tion (selection bias)
Low risk Sequential random numbers
Allocation concealment
(selection bias)
Low risk Central randomisation
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data balanced between groups
Selective reporting (re-
porting bias)
Low risk All of outcomes have been reported
Other bias High risk Supported by American Regent, Inc
Van Wyck 2005 CKD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Single tertiary centre• Country: China• Health status: Stable adult HD patients on ESA therapy• Number: IV iron (21); oral iron (22)• Age: NS• Sex (M/F): NS
Exclsuion criteria
• NS
Interventions IV iron
• Ferric citrate• Dose, duration, frequency: 50 mg twice/week for 5 weeks* Total dose of elemental iron: 500 mg
Oral iron
• Ferrous sulphate• Dose, duration, frequency: 600 mg/day for 5 weeks* Total dose of elemental iron: 6300 mg
Co-interventions
• EPO 6000 U/week. Unclear when started. Stable dose.
Outcomes • Hb at end of study (5 weeks)• Ferritin at end of study (5 weeks)
Notes • Abstract only
Wang 2003 HD 
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• Funding source: NS - abstract only• Follow-up period: 5 weeks• Lost to follow-up: Unclear. Reported to have enrolled 45 patients, but 21 included in IV arm and 22
in oral arm• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: None requested
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract only
Allocation concealment
(selection bias)
Unclear risk Abstract only
Blinding (performance
bias and detection bias)
Low risk Abstract only. Outcome is laboratory based and unlike to be altered by blind-
ing.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Abstract only
Selective reporting (re-
porting bias)
Unclear risk Abstract only. Reported end Hb and ferritin
Other bias Unclear risk Abstract only
Wang 2003 HD  (Continued)
 
 
Methods Study design: parallel RCT
Study duration/time frame: NS
Participants Inclusion criteria
• Setting: Multicentre• Country: USA• Health status: Patients aged > 1 year to < 20 years; HD > 2 months; TSAT > 20%; stable ESA > 4 weeks
prior to study; urea reduction ratio > 60%• Number: IV iron (17); oral iron (18)• Mean age ± SD: IV iron (181.4 months ± 54.8); oral iron (175.9 months ± 41.9)• Sex (M/F): IV iron (7/10); oral iron (9/9)
Exclusion criteria
• Non-renal cause of anaemia; malignancy; serious reaction to IV iron; active infection or inflammation;
HIV, iron overload (ferritin > 800 ng/mL); hyperparathyroidism (PTH > 1000 pg/mL); uncontrolled HTN
Interventions IV iron
• Iron dextran• Dose, duration, frequency: 12 doses weekly. Dose differed according to body weight* Total dose of elemental iron could not be calculated
Warady 2002 HD 
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Oral iron
• Ferrous fumarate• Dose, duration, frequency: 5 mg/kg/day for 16 weeks* Total dose of oral iron: 560 mg/kg
Co-intervention
• ESA use, dose variable
Outcomes • Final or change in Hb (16 weeks)• Final or change in ferritin (16 weeks)• Final or change in TSAT (16 weeks)• Final or change in mean ESA dose (16 weeks)• Final or change in CHr (16 weeks)• Number with change in ESA dose
Notes • Funding source: Watson Laboratories• Follow-up period: 16 weeks• Lost to follow-up: None• Exclusions post randomisation but pre-intervention: NS• Stop or end points: NS• Additional data requested from authors: We contacted authors to seek method of allocation conceal-
ment, and to investigate if all patients were included in the analysis. Some data were obtained from
authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table
Allocation concealment
(selection bias)
Unclear risk Method of allocation not mentioned
Blinding (performance
bias and detection bias)
Low risk Laboratory outcomes unlikely to be affected by lack of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were included in the analysis (information from authors)
Selective reporting (re-
porting bias)
Low risk All of outcomes have been reported
Other bias High risk Supported by a grant from Watson Laboratories
Warady 2002 HD  (Continued)
ACE: angiotensin-converting enzyme; ACEi: angiotensin-converting enzyme inhibitor; CAD: coronary artery disease; CAPD: continuous
ambulatory peritoneal dialysis; CHF: congestive heart failure; CHr: reticulocyte haemoglobin content; CKD: chronic kidney disease;
Cr: creatinine; CrCl: creatinine clearance; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; EPO: erythropoietin; ESA:
erythrocyte-stimulating agent; FOBT: faecal occult blood test; GFR: glomerular filtration rate; Hb: haemoglobin; Hct: haematocrit; HCV:
hepatitis C virus; HD: haemodialysis; HIV: human immunosuppressive virus; HTN: hypertension; IHD: ischaemic heart disease; IQR:
interquartile range; IV: intravenous; NS - not stated; PCKD: polycystic kidney disease; PCV: packed cell volume; PD: peritoneal dialysis; PTH:
parathyroid hormone; SFGC: sodium ferrigluconate complex; TIBC: total iron binding capacity; TSAT: transferrin saturation
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahsan 2000 Sequential study, not RCT
Allegra 1991 Results included some non-randomised patients
Jenq 2005 Non-randomised comparator study, not RCT
Johnson 2001 Sequential study, not RCT
Lye 1997 RCT comparing intramuscular and oral routes
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A clinical trial of oral versus IV iron in patients with chronic kidney disease
Methods Phase IV randomised, controlled open-label trial comparing IV iron with oral iron
Participants Non dialysis dependent CKD with GFR < 60 ml/min and renal anaemia
Interventions IV iron compared with oral ferrous sulphate
Outcomes Mean rate of decline in GFR in the two groups - oral and IV iron at 2 years
Proteinuria at 2 years
Starting date August 2008
Contact information Jennifer E Bills, BS (jebills@iupui.edu)
Notes  
Agarwal 2008 
 
 
Trial name or title Iron isomaltoside (Monofer) in non-dialysis dependent chronic kidney disease and with renal relat-
ed anaemia
Methods Phase III randomised comparative open-label study of IV iron (isomaltose 1000) administered by in-
fusions or repeated bolus injections compared with oral iron sulphate
Participants 350 non-dialysis dependent CKD patients with renal related anaemia
Interventions IV Isomaltoside or oral iron sulphate
Outcomes Change in haemoglobin concentration from baseline to week 8
Starting date April 2010
Contact information Pharmacosmos A/S
Monofer 2010 CKD 
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Notes Estimated to be complete in September 2011
Monofer 2010 CKD  (Continued)
 
 
Trial name or title Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal
transplant patients
Methods Single centre prospective, open-label, randomised, controlled trial
Participants 100 renal transplant recipients
Interventions Single dose of 500 mg iron polymaltose (within 5 days of transplant) or oral ferrous sulphate (2
slow release tablets daily)
Outcomes Time to normalisation of haemoglobin post transplant
Starting date 2009
Contact information Dr David Mudge (david_mudge@health.qld.gov.au)
Notes Protocol published in BMC Nephrology
Mudge 2009 TX 
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Intravenous versus oral iron therapy: primary outcomes
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Haemoglobin: Final or change (all pa-
tients)
22 1862 Mean Difference (IV, Random, 95% CI) 0.90 [0.44, 1.37]
2 Number achieving target haemoglobin
or increase ≥1 g/dL
10 1344 Risk Ratio (M-H, Random, 95% CI) 1.70 [1.36, 2.12]
3 Ferritin: Final or change (all patients) 24 1751 Mean Difference (IV, Random, 95% CI) 243.25 [188.74,
297.75]
4 Transferrin saturation: Final or change 18 1457 Mean Difference (IV, Random, 95% CI) 10.20 [5.56, 14.83]
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Analysis 1.1.   Comparison 1 Intravenous versus oral iron therapy: primary
outcomes, Outcome 1 Haemoglobin: Final or change (all patients).
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Lye 2000 HD 30 9.1 (1.4) 30 9.4 (1.5) 4.41% -0.3[-1.03,0.43]
Warady 2002 HD 17 11.2 (1.3) 18 11.4 (0.8) 4.4% -0.24[-0.98,0.5]
McMahon 2009 CKD 39 11.8 (1) 38 11.9 (1.2) 4.69% -0.1[-0.59,0.39]
Michael 2007 HD 33 -0.2 (1.1) 27 -0.2 (1.1) 4.63% 0[-0.55,0.55]
Agarwal 2006 CKD 36 0.4 (0.8) 39 0.2 (0.9) 4.79% 0.2[-0.18,0.58]
Qunibi 2007 CKD 147 1 (0.8) 103 0.7 (0.9) 4.9% 0.3[0.08,0.52]
Charytan 2005 CKD 39 11.1 (1.1) 44 10.7 (1) 4.73% 0.4[-0.05,0.85]
Van Wyck 2005 CKD 72 10.9 (1) 71 10.4 (1.1) 4.81% 0.5[0.15,0.85]
Provenzano 2009 HD 114 11.7 (1.2) 116 11.2 (1.2) 4.84% 0.5[0.19,0.81]
Macdougall 1999 HD,PD 41 10.8 (1.4) 35 10.3 (1.1) 4.62% 0.5[-0.06,1.06]
Leehey 2005 CKD 24 1.5 (0.9) 24 0.8 (0.9) 4.67% 0.7[0.19,1.21]
Spinowitz 2008 CKD 228 10.9 (1.3) 76 10.2 (1) 4.86% 0.73[0.45,1.01]
Souza 1997 HD 8 1 (0.9) 11 0.2 (0.8) 4.37% 0.8[0.04,1.56]
Broumand 1998 HD 9 9.8 (1.1) 8 9 (1) 4.04% 0.8[-0.19,1.79]
Hussain 1998 HD 10 11.6 (0.6) 10 10.5 (1.1) 4.3% 1.1[0.29,1.91]
Macdougall 1996 HD,PD,CKD 9 11.7 (1.3) 11 10.6 (1.4) 3.75% 1.1[-0.09,2.29]
Aggarwal 2003 CKD 20 10.1 (0.9) 20 8.9 (1.2) 4.52% 1.11[0.46,1.76]
Wang 2003 HD 21 9.3 (1.8) 22 7.9 (1.4) 4.07% 1.4[0.43,2.37]
Li 2008 PD 26 12.2 (1.1) 20 10.6 (1) 4.56% 1.58[0.97,2.19]
Erten 1998 HD 26 11.8 (1.3) 22 9.9 (0.9) 4.54% 1.9[1.27,2.53]
Li 2008 HD 70 12 (1.3) 66 10 (1.1) 4.78% 1.99[1.6,2.38]
Fudin 1998 HD 20 11 (0.9) 12 6.1 (0.4) 4.73% 4.92[4.47,5.37]
   
Total *** 1039   823   100% 0.9[0.44,1.37]
Heterogeneity: Tau2=1.14; Chi2=449.44, df=21(P<0.0001); I2=95.33%  
Test for overall effect: Z=3.8(P=0)  
Favours oral iron 105-10 -5 0 Favours IV iron
 
 
Analysis 1.2.   Comparison 1 Intravenous versus oral iron therapy: primary
outcomes, Outcome 2 Number achieving target haemoglobin or increase ≥1 g/dL.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Stoves 2001 CKD 13/18 16/20 12.08% 0.9[0.63,1.29]
Van Wyck 2005 CKD 47/79 35/82 13.19% 1.39[1.02,1.9]
Li 2008 PD 23/26 11/20 10.84% 1.61[1.06,2.45]
Charytan 2005 CKD 21/39 14/44 8.96% 1.69[1.01,2.85]
Qunibi 2007 CKD 89/147 36/103 13.54% 1.73[1.29,2.32]
Hussain 1998 HD 9/10 5/10 6.98% 1.8[0.94,3.46]
Provenzano 2009 HD 56/114 29/116 11.96% 1.96[1.36,2.83]
Spinowitz 2008 CKD 89/228 14/76 9.32% 2.12[1.29,3.49]
Li 2008 HD 45/70 19/66 10.89% 2.23[1.47,3.39]
Macdougall 1999 HD,PD 19/41 2/35 2.23% 8.11[2.03,32.41]
   
Total (95% CI) 772 572 100% 1.7[1.36,2.12]
Total events: 411 (IV iron), 181 (Oral iron)  
Heterogeneity: Tau2=0.07; Chi2=23.17, df=9(P=0.01); I2=61.15%  
Favours oral iron 500.02 100.1 1 Favours IV iron
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Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=4.69(P<0.0001)  
Favours oral iron 500.02 100.1 1 Favours IV iron
 
 
Analysis 1.3.   Comparison 1 Intravenous versus oral iron therapy:
primary outcomes, Outcome 3 Ferritin: Final or change (all patients).
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Svara 1996 HD 29 166 (123) 28 109 (114) 4.59% 57[-4.54,118.54]
Li 2008 HD 70 495.7
(315.2)
66 400.3
(264.1)
4.22% 95.4[-2.13,192.93]
Michael 2007 HD 33 80 (147) 27 -31 (130) 4.51% 111[40.86,181.14]
Leehey 2005 CKD 24 132 (162) 24 19 (162) 4.29% 113[21.34,204.66]
Warady 2002 HD 17 259.1
(163.1)
18 122 (118.8) 4.25% 137.1[42.11,232.09]
Aggarwal 2003 CKD 20 267 (58.8) 20 104.4 (25.3) 4.82% 162.63[134.56,190.7]
Fudin 1998 HD 20 393.5
(249.3)
10 229.7
(113.6)
3.82% 163.8[33.82,293.78]
Li 2008 PD 26 466.7 (85.3) 20 299.4 (83.2) 4.69% 167.3[118.26,216.34]
Agarwal 2006 CKD 36 232 (160.8) 39 55.9 (236.2) 4.3% 176.1[85.25,266.95]
Van Wyck 2005 CKD 72 323 (178.5) 72 132 (90.3) 4.71% 191[144.79,237.21]
Lye 2000 HD 30 432 (288) 30 231 (204) 3.87% 201[74.71,327.29]
Wang 2003 HD 21 496 (306) 22 279 (206) 3.48% 217[60.35,373.65]
Broumand 1998 HD 9 779 (205) 8 546.5 (139) 3.37% 232.5[67.53,397.47]
Souza 1997 HD 8 245 (133) 11 2.3 (77.2) 4.16% 242.7[139.86,345.54]
McMahon 2009 CKD 39 412 (206) 38 153 (88) 4.51% 259[188.55,329.45]
Macdougall 1999 HD,PD 41 432 (202) 35 140 (91) 4.53% 292[223.21,360.79]
Charytan 2005 CKD 39 288 (150) 44 -5.1 (151) 4.56% 293.1[228.24,357.96]
Hussain 1998 HD 10 671 (388) 10 367 (238) 2.11% 304[21.88,586.12]
Provenzano 2009 HD 114 601.8 (283) 116 289.3
(165.8)
4.61% 312.49[252.43,372.55]
Macdougall 1996 HD,PD,CKD 9 490 (276) 11 165 (95) 3.08% 325[136.15,513.85]
Erten 1998 HD 26 573 (246.7) 22 247.4
(187.7)
3.91% 325.6[202.54,448.66]
Spinowitz 2008 CKD 228 555.7 (320) 76 160.8 (161) 4.65% 394.9[339.8,450]
Kotaki 1997 HD 15 750 (147) 16 255 (64) 4.41% 495[414.27,575.73]
Fishbane 1995 HD 20 753.9 (135) 32 157.3 (87) 4.55% 596.6[530.2,663]
   
Total *** 956   795   100% 243.25[188.74,297.75]
Heterogeneity: Tau2=15848.34; Chi2=303.54, df=23(P<0.0001); I2=92.42%  
Test for overall effect: Z=8.75(P<0.0001)  
Favours oral iron 1000500-1000 -500 0 Favours IV iron
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Analysis 1.4.   Comparison 1 Intravenous versus oral iron therapy:
primary outcomes, Outcome 4 Transferrin saturation: Final or change.
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Macdougall 1996 HD,PD,CKD 12 23 (4) 13 31 (4) 5.95% -8[-11.14,-4.86]
Michael 2007 HD 33 -0.6 (9.1) 27 -1.1 (8.4) 5.79% 0.5[-3.94,4.94]
Van Wyck 2005 CKD 72 25 (8.9) 72 22.2 (9.4) 5.96% 2.8[-0.2,5.8]
Charytan 2005 CKD 39 4.5 (8.3) 44 0.5 (8.5) 5.9% 4[0.38,7.62]
Svara 1996 HD 29 26.8 (11.1) 28 22.2 (9.6) 5.65% 4.6[-0.78,9.98]
Kotaki 1997 HD 15 35.7 (5.1) 16 30.6 (1.9) 5.99% 5.1[2.36,7.84]
Agarwal 2006 CKD 36 8.3 (7.5) 39 2.9 (8.8) 5.89% 5.4[1.71,9.09]
Provenzano 2009 HD 114 22.3 (13.3) 116 16.5 (9.7) 5.96% 5.85[2.83,8.87]
McMahon 2009 CKD 39 30 (9) 38 24 (11) 5.78% 6[1.5,10.5]
Spinowitz 2008 CKD 228 21 (10.1) 76 11.8 (6.7) 6.05% 9.2[7.2,11.2]
Li 2008 HD 70 39.6 (16.7) 66 28.6 (18.4) 5.56% 11[5.08,16.92]
Li 2008 PD 26 37.8 (16.1) 20 25.7 (17.5) 4.79% 12.1[2.25,21.95]
Warady 2002 HD 17 44.1 (14.1) 18 31.3 (15) 4.84% 12.73[3.11,22.35]
Fudin 1998 HD 20 33.2 (3.5) 10 19.9 (5.4) 5.89% 13.31[9.63,16.99]
Hussain 1998 HD 10 44.6 (19.8) 10 29 (11) 3.92% 15.61[1.57,29.65]
Ahsan 1997 TX 6 38 (8.2) 6 22 (3.4) 5.35% 16[8.9,23.1]
Aggarwal 2003 CKD 20 64.9 (11) 20 45.7 (14.1) 5.2% 19.23[11.39,27.07]
Fishbane 1995 HD 20 74.8 (13) 32 19.8 (5.7) 5.54% 55[48.98,61.02]
   
Total *** 806   651   100% 10.2[5.56,14.83]
Heterogeneity: Tau2=91.51; Chi2=391.08, df=17(P<0.0001); I2=95.65%  
Test for overall effect: Z=4.31(P<0.0001)  
Favours oral iron 10050-100 -50 0 Favours IV iron
 
 
Comparison 2.   Intravenous versus oral iron therapy: secondary outcomes
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 End of treatment or change in
ESA dose
9 487 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-1.22, -0.30]
2 Number requiring increase in
ESA dose
2 45 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.11, 1.06]
3 Number requiring decrease or
cessation of ESA
4 150 Risk Ratio (M-H, Random, 95% CI) 2.02 [0.69, 5.91]
4 All-cause mortality 5 435 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.35, 3.84]
5 Cardiovascular mortality 2 70 Risk Ratio (M-H, Random, 95% CI) 3.20 [0.37, 27.51]
6 Numbers of non-dialysis pa-
tients needing to commence dial-
ysis
3 282 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.28, 1.71]
7 Haematocrit 4   Mean Difference (IV, Random, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7.1 All studies 4 152 Mean Difference (IV, Random, 95% CI) 1.18 [-2.17, 4.52]
7.2 Excluding studies in which the
aim was to maintain haematocrit
unchanged
3 121 Mean Difference (IV, Random, 95% CI) 2.43 [0.42, 4.44]
8 Reticulocyte haemoglobin con-
centration (CHr)
4 506 Mean Difference (IV, Random, 95% CI) 0.67 [0.29, 1.05]
 
 
Analysis 2.1.   Comparison 2 Intravenous versus oral iron therapy:
secondary outcomes, Outcome 1 End of treatment or change in ESA dose.
Study or subgroup IV iron Oral iron Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Li 2008 HD 70 4500 (1049) 66 6140 (1014) 12.84% -1.58[-1.97,-1.19]
Fishbane 1995 HD 20 4050 (2455) 32 7563 (2138) 11.1% -1.53[-2.17,-0.89]
Li 2008 PD 26 6100 (1043) 26 7635 (1024) 11.25% -1.46[-2.08,-0.85]
Hussain 1998 HD 10 3400 (1356) 10 4600 (1356) 8.98% -0.85[-1.77,0.08]
Warady 2002 HD 17 -76.3
(104.7)
18 -30.9 (77.7) 10.83% -0.48[-1.16,0.19]
Macdougall 1996 HD,PD,CKD 12 1202 (229) 13 1294 (314) 9.95% -0.32[-1.11,0.47]
Macdougall 1999 HD,PD 41 74 (36) 35 84 (53) 12.42% -0.22[-0.67,0.23]
Michael 2007 HD 33 -28.4
(103.6)
27 -12.6 (79.7) 12.03% -0.17[-0.68,0.34]
Kotaki 1997 HD 15 3760 (1762) 16 4025 (2168) 10.59% -0.13[-0.84,0.58]
   
Total *** 244   243   100% -0.76[-1.22,-0.3]
Heterogeneity: Tau2=0.39; Chi2=42.96, df=8(P<0.0001); I2=81.38%  
Test for overall effect: Z=3.25(P=0)  
Favours IV iron 42-4 -2 0 Favours oral iron
 
 
Analysis 2.2.   Comparison 2 Intravenous versus oral iron therapy:
secondary outcomes, Outcome 2 Number requiring increase in ESA dose.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hussain 1998 HD 2/10 6/10 71.54% 0.33[0.09,1.27]
Macdougall 1996 HD,PD,CKD 1/12 3/13 28.46% 0.36[0.04,3.02]
   
Total (95% CI) 22 23 100% 0.34[0.11,1.06]
Total events: 3 (IV iron), 9 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=1.86(P=0.06)  
IV iron 1000.01 100.1 1 Oral iron
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Analysis 2.3.   Comparison 2 Intravenous versus oral iron therapy: secondary
outcomes, Outcome 3 Number requiring decrease or cessation of ESA.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Stoves 2001 CKD 7/18 10/20 29.33% 0.78[0.38,1.61]
Macdougall 1996 HD,PD,CKD 5/12 4/13 25.51% 1.35[0.47,3.89]
Warady 2002 HD 11/17 6/18 29.16% 1.94[0.92,4.08]
Fishbane 1995 HD 15/20 1/32 15.99% 24[3.43,167.95]
   
Total (95% CI) 67 83 100% 2.02[0.69,5.91]
Total events: 38 (IV iron), 21 (Oral iron)  
Heterogeneity: Tau2=0.88; Chi2=14.09, df=3(P=0); I2=78.71%  
Test for overall effect: Z=1.29(P=0.2)  
IV iron 2000.005 100.1 1 Oral iron
 
 
Analysis 2.4.   Comparison 2 Intravenous versus oral iron
therapy: secondary outcomes, Outcome 4 All-cause mortality.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fishbane 1995 HD 0/20 3/32 14.98% 0.22[0.01,4.13]
Provenzano 2009 HD 1/114 3/116 23.32% 0.34[0.04,3.21]
Fudin 1998 HD 2/20 1/12 22.61% 1.2[0.12,11.87]
Stoves 2001 CKD 1/18 0/20 13.1% 3.32[0.14,76.6]
McMahon 2009 CKD 5/41 1/42 25.99% 5.12[0.63,41.97]
   
Total (95% CI) 213 222 100% 1.16[0.35,3.84]
Total events: 9 (IV iron), 8 (Oral iron)  
Heterogeneity: Tau2=0.29; Chi2=4.72, df=4(P=0.32); I2=15.19%  
Test for overall effect: Z=0.24(P=0.81)  
IV iron 1000.01 100.1 1 Oral iron
 
 
Analysis 2.5.   Comparison 2 Intravenous versus oral iron therapy:
secondary outcomes, Outcome 5 Cardiovascular mortality.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fudin 1998 HD 2/20 0/12 53% 3.1[0.16,59.52]
Stoves 2001 CKD 1/18 0/20 47% 3.32[0.14,76.6]
   
Total (95% CI) 38 32 100% 3.2[0.37,27.51]
Total events: 3 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
Favours oral iron 1000.01 100.1 1 Favours IV iron
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Analysis 2.6.   Comparison 2 Intravenous versus oral iron therapy: secondary
outcomes, Outcome 6 Numbers of non-dialysis patients needing to commence dialysis.
Study or subgroup IV iron Oral iron Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McMahon 2009 CKD 1/41 3/42 16.65% 0.34[0.04,3.15]
Stoves 2001 CKD 3/18 5/20 50.02% 0.67[0.19,2.4]
Van Wyck 2005 CKD 3/79 3/82 33.34% 1.04[0.22,4.99]
   
Total (95% CI) 138 144 100% 0.69[0.28,1.71]
Total events: 7 (IV iron), 11 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=0.65, df=2(P=0.72); I2=0%  
Test for overall effect: Z=0.8(P=0.42)  
IV iron 1000.01 100.1 1 Oral iron
 
 
Analysis 2.7.   Comparison 2 Intravenous versus oral iron therapy: secondary outcomes, Outcome 7 Haematocrit.
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.7.1 All studies  
Kotaki 1997 HD 15 33.2 (0.9) 16 35.7 (0.7) 26.2% -2.5[-3.07,-1.93]
Svara 1996 HD 29 27.8 (3.4) 28 27.2 (2.9) 24.83% 0.6[-1.04,2.24]
Fishbane 1995 HD 20 34.4 (3.1) 32 31.8 (2.3) 24.93% 2.6[1.02,4.18]
Ahsan 1997 TX 6 37.7 (1.7) 6 33.4 (1.9) 24.04% 4.3[2.26,6.34]
Subtotal *** 70   82   100% 1.18[-2.17,4.52]
Heterogeneity: Tau2=11.03; Chi2=74.54, df=3(P<0.0001); I2=95.98%  
Test for overall effect: Z=0.69(P=0.49)  
   
2.7.2 Excluding studies in which the aim was to maintain haematocrit un-
changed
 
Svara 1996 HD 29 27.8 (3.4) 28 27.2 (2.9) 34.43% 0.6[-1.04,2.24]
Fishbane 1995 HD 20 34.4 (3.1) 32 31.8 (2.3) 35% 2.6[1.02,4.18]
Ahsan 1997 TX 6 37.7 (1.7) 6 33.4 (1.9) 30.57% 4.3[2.26,6.34]
Subtotal *** 55   66   100% 2.43[0.42,4.44]
Heterogeneity: Tau2=2.35; Chi2=7.96, df=2(P=0.02); I2=74.88%  
Test for overall effect: Z=2.37(P=0.02)  
Favours oral iron 105-10 -5 0 Favours IV iron
 
 
Analysis 2.8.   Comparison 2 Intravenous versus oral iron therapy: secondary
outcomes, Outcome 8 Reticulocyte haemoglobin concentration (CHr).
Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Warady 2002 HD 17 30.2 (2.8) 18 30.4 (2.5) 4.63% -0.25[-2.03,1.53]
Provenzano 2009 HD 114 32.2 (2.7) 116 31.6 (2.4) 33.86% 0.66[0,1.32]
Agarwal 2006 CKD 36 1 (1.2) 39 0.3 (1.7) 34.43% 0.7[0.05,1.35]
Van Wyck 2005 CKD 84 33.1 (2.2) 82 32.3 (2.6) 27.08% 0.8[0.06,1.54]
   
Total *** 251   255   100% 0.67[0.29,1.05]
Favours oral iron 42-4 -2 0 Favours IV iron
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Study or subgroup IV iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0; Chi2=1.16, df=3(P=0.76); I2=0%  
Test for overall effect: Z=3.43(P=0)  
Favours oral iron 42-4 -2 0 Favours IV iron
 
 
Comparison 3.   Adverse e:ects
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Any adverse event 12 1458 Risk Difference (M-H, Random,
95% CI)
-0.09 [-0.19, 0.00]
2 Type of adverse event 12   Risk Difference (M-H, Random,
95% CI)
Subtotals only
2.1 Allergic reactions/hypotension 8 1199 Risk Difference (M-H, Random,
95% CI)
0.02 [-0.00, 0.04]
2.2 All gastrointestinal adverse effects 8 925 Risk Difference (M-H, Random,
95% CI)
-0.17 [-0.27, -0.06]
2.3 Constipation 5 691 Risk Difference (M-H, Random,
95% CI)
-0.07 [-0.14, 0.00]
2.4 Diarrhoea 5 698 Risk Difference (M-H, Random,
95% CI)
-0.03 [-0.06, -0.00]
2.5 Nausea or vomiting 4 646 Risk Difference (M-H, Random,
95% CI)
-0.04 [-0.10, 0.02]
2.6 Taste disturbances 3 557 Risk Difference (M-H, Random,
95% CI)
0.04 [-0.02, 0.09]
2.7 Iron overload 2 55 Risk Difference (M-H, Random,
95% CI)
0.07 [-0.16, 0.30]
2.8 Number discontinuing treatment
because of adverse effects
1 182 Risk Difference (M-H, Random,
95% CI)
0.03 [-0.01, 0.07]
 
 
Analysis 3.1.   Comparison 3 Adverse e:ects, Outcome 1 Any adverse event.
Study or subgroup IV iron Oral iron Risk Difference Weight Risk Difference
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Li 2008 PD 0/26 8/20 6.91% -0.4[-0.62,-0.18]
Charytan 2005 CKD 10/39 28/44 7.31% -0.38[-0.58,-0.18]
Li 2008 HD 0/70 22/66 9.1% -0.33[-0.45,-0.22]
Qunibi 2007 CKD 4/147 27/103 9.57% -0.23[-0.32,-0.15]
Spinowitz 2008 CKD 23/217 18/75 9.28% -0.13[-0.24,-0.03]
IV iron 10.5-1 -0.5 0 Oral iron
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Study or subgroup IV iron Oral iron Risk Difference Weight Risk Difference
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Provenzano 2009 HD 54/110 64/113 8.77% -0.08[-0.21,0.06]
Aggarwal 2003 CKD 0/20 0/20 9.52% 0[-0.09,0.09]
Van Wyck 2005 CKD 20/91 17/91 9.06% 0.03[-0.08,0.15]
Fishbane 1995 HD 1/20 0/32 9.04% 0.05[-0.07,0.17]
Stoves 2001 CKD 3/22 1/23 8.01% 0.09[-0.07,0.26]
Agarwal 2006 CKD 13/44 9/45 7.73% 0.1[-0.08,0.27]
Hussain 1998 HD 2/10 0/10 5.69% 0.2[-0.08,0.48]
   
Total (95% CI) 816 642 100% -0.09[-0.19,0]
Total events: 130 (IV iron), 194 (Oral iron)  
Heterogeneity: Tau2=0.02; Chi2=72.22, df=11(P<0.0001); I2=84.77%  
Test for overall effect: Z=1.87(P=0.06)  
IV iron 10.5-1 -0.5 0 Oral iron
 
 
Analysis 3.2.   Comparison 3 Adverse e:ects, Outcome 2 Type of adverse event.
Study or subgroup IV iron Oral iron Risk Difference Weight Risk Difference
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 Allergic reactions/hypotension  
Qunibi 2007 CKD 0/147 0/103 27.36% 0[-0.02,0.02]
Charytan 2005 CKD 0/39 0/44 11.27% 0[-0.05,0.05]
Provenzano 2009 HD 2/110 0/113 18.3% 0.02[-0.01,0.05]
Spinowitz 2008 CKD 4/217 0/75 20.66% 0.02[-0.01,0.04]
Van Wyck 2005 CKD 2/91 0/91 15.05% 0.02[-0.01,0.06]
Warady 2002 HD 1/17 0/18 1.58% 0.06[-0.09,0.21]
Agarwal 2006 CKD 3/44 0/45 4.42% 0.07[-0.02,0.15]
Stoves 2001 CKD 3/22 0/23 1.38% 0.14[-0.02,0.29]
Subtotal (95% CI) 687 512 100% 0.02[-0,0.04]
Total events: 15 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=12.63, df=7(P=0.08); I2=44.58%  
Test for overall effect: Z=1.69(P=0.09)  
   
3.2.2 All gastrointestinal adverse effects  
Li 2008 PD 0/26 8/20 9.7% -0.4[-0.62,-0.18]
Charytan 2005 CKD 10/39 28/44 10.36% -0.38[-0.58,-0.18]
Li 2008 HD 0/70 22/66 13.44% -0.33[-0.45,-0.22]
Spinowitz 2008 CKD 10/217 15/75 14.12% -0.15[-0.25,-0.06]
Van Wyck 2005 CKD 8/91 16/91 14.03% -0.09[-0.19,0.01]
Agarwal 2006 CKD 7/44 11/45 11.54% -0.09[-0.25,0.08]
Stoves 2001 CKD 0/22 1/23 13.48% -0.04[-0.16,0.07]
Fishbane 1995 HD 1/20 0/32 13.33% 0.05[-0.07,0.17]
Subtotal (95% CI) 529 396 100% -0.17[-0.27,-0.06]
Total events: 36 (IV iron), 101 (Oral iron)  
Heterogeneity: Tau2=0.02; Chi2=39.73, df=7(P<0.0001); I2=82.38%  
Test for overall effect: Z=3.01(P=0)  
   
3.2.3 Constipation  
Charytan 2005 CKD 5/39 16/44 10.39% -0.24[-0.41,-0.06]
Van Wyck 2005 CKD 1/91 8/91 23.55% -0.08[-0.14,-0.01]
IV iron 10.5-1 -0.5 0 Oral iron
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Study or subgroup IV iron Oral iron Risk Difference Weight Risk Difference
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Spinowitz 2008 CKD 1/217 6/75 23.54% -0.08[-0.14,-0.01]
Stoves 2001 CKD 0/22 1/23 16.57% -0.04[-0.16,0.07]
Agarwal 2006 CKD 0/44 0/45 25.96% 0[-0.04,0.04]
Subtotal (95% CI) 413 278 100% -0.07[-0.14,0]
Total events: 7 (IV iron), 31 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=18.21, df=4(P=0); I2=78.03%  
Test for overall effect: Z=1.86(P=0.06)  
   
3.2.4 Diarrhoea  
Charytan 2005 CKD 0/39 3/44 10.79% -0.07[-0.15,0.02]
Spinowitz 2008 CKD 3/217 4/75 27.9% -0.04[-0.09,0.01]
Van Wyck 2005 CKD 0/91 3/91 44.98% -0.03[-0.07,0.01]
Agarwal 2006 CKD 2/44 2/45 10.64% 0[-0.09,0.09]
Fishbane 1995 HD 1/20 0/32 5.69% 0.05[-0.07,0.17]
Subtotal (95% CI) 411 287 100% -0.03[-0.06,-0]
Total events: 6 (IV iron), 12 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=3.19, df=4(P=0.53); I2=0%  
Test for overall effect: Z=2.11(P=0.03)  
   
3.2.5 Nausea or vomiting  
Charytan 2005 CKD 2/39 9/44 13.63% -0.15[-0.29,-0.02]
Spinowitz 2008 CKD 4/217 5/75 33.42% -0.05[-0.11,0.01]
Van Wyck 2005 CKD 2/91 5/91 34.74% -0.03[-0.09,0.02]
Agarwal 2006 CKD 5/44 2/45 18.21% 0.07[-0.04,0.18]
Subtotal (95% CI) 391 255 100% -0.04[-0.1,0.02]
Total events: 13 (IV iron), 21 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=6.43, df=3(P=0.09); I2=53.31%  
Test for overall effect: Z=1.18(P=0.24)  
   
3.2.6 Taste disturbances  
Spinowitz 2008 CKD 2/217 0/75 45.23% 0.01[-0.01,0.03]
Van Wyck 2005 CKD 5/91 0/91 34.49% 0.05[0,0.11]
Charytan 2005 CKD 3/39 0/44 20.27% 0.08[-0.02,0.17]
Subtotal (95% CI) 347 210 100% 0.04[-0.02,0.09]
Total events: 10 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0; Chi2=7.03, df=2(P=0.03); I2=71.56%  
Test for overall effect: Z=1.39(P=0.16)  
   
3.2.7 Iron overload  
Warady 2002 HD 0/17 0/18 64.03% 0[-0.1,0.1]
Hussain 1998 HD 2/10 0/10 35.97% 0.2[-0.08,0.48]
Subtotal (95% CI) 27 28 100% 0.07[-0.16,0.3]
Total events: 2 (IV iron), 0 (Oral iron)  
Heterogeneity: Tau2=0.02; Chi2=2.67, df=1(P=0.1); I2=62.57%  
Test for overall effect: Z=0.61(P=0.54)  
   
3.2.8 Number discontinuing treatment because of adverse effects  
Van Wyck 2005 CKD 3/91 0/91 100% 0.03[-0.01,0.07]
Subtotal (95% CI) 91 91 100% 0.03[-0.01,0.07]
Total events: 3 (IV iron), 0 (Oral iron)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.54(P=0.12)  
IV iron 10.5-1 -0.5 0 Oral iron
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  Total
studies
(N)
Studies MD (95% CI) (g/dL) P
Dose IV iron/study month 
≥ 400 mg/month 9 4 0.51 (-0.25 to 1.28) 0.46
> 400 to 700 mg/month 5 5 1.17 (0.41 to 1.94)  
> 700 mg/month 8 7 0.73 (0.43, 1.03)  
Dose IV iron (mg total dose)
≥ 1000 mg 8 6 0.59 (0.30 to 0.87) 0.21
1000 to 1999 mg 10 7 0.80 (0.25 to 1.37)  
> 2000 mg 4 3 1.34 (0.67 to 2.02)  
Oral dose iron/study month
< 4000 mg/month 6 4 2.01 (0.74 to 3.88) 0.04
≥ 4000 and < 6000 mg/month 9 9 0.98 (0.47 to 1.50)  
≥ 6000 mg/month 7 5 0.32 (0.12 to 0.52)  
Dose oral iron (mg total dose)
≥ 12,000 mg 7 7 0.91 (0.55 to 1.28) 0.66
1200 to 30,000 mg 10 7 0.91 (0.33 to 1.48)  
> 30,000 mg 7 4 1.36 (-1.54 to 4.26)  
Any ESA use 
No EPO 9 7 1.05 (-0.01 to 2.10) 0.30
EPO 19 15 1.02 (0.48 to 1.56)  
ESA timing of use 
Start of study 7 5 1.22 (-0.33 to 2.77) 0.61
Before study 12 8 0.88 (0.34 to 1.42)  
CKD stage 
1 to 5 9 8 0.45 (0.24 to 0.66) 0.27
Table 1.   Subgroup analysis and meta-regression to examine heterogeneity in haemoglobin meta-analyses 
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Dialysis (5D) 18 13 1.16 (0.30 to 2.02)  
Study duration 
≥ 2 months 10 9 0.60 (0.37 to 0.82) 0.44
> 2 to ≤ 4 months 7 5 1.03 (0.2 to 1.86)  
> 4 months 9 7 1.11 (-0.35 to 2.75)  
Intervention aim 
Increase Hb 24 20 1.00 (0.51 to 1.50) 0.18
Maintain Hb 4 2 -0.09 (-0.53 to 0.36)  
Pharmaceutical company sponsorship
Unclear 16 12 1.42 (0.52 to 2.33) 0.01
Sponsored 12 10 0.36 (0.19 to 0.53)  
Imputed standard deviation 
Not imputed   18 0.38 (0.20 to 0.56) 0.48
imputed   4 0.98 (0.40 to 1.57)  
Table 1.   Subgroup analysis and meta-regression to examine heterogeneity in haemoglobin meta-analyses  (Continued)
CKD: chronic kidney disease; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin
 
 
  Total
studies
(N)
Studies MD (95% CI) (µg/L) P
Dose IV iron/study month
≥ 400 mg/month 9 7 263 (112 to 415) 0.12
> 400 to 700 mg/month 5 5 235 (155 to 315)  
>700 mg/month 8 7 240 (149 to 332)  
Dose IV iron (mg total dose) 
≥ 1000 mg 8 7 170 (118 to 223) 0.01
1000 to 1999 mg 10 8 262 (161 to 364)  
> 2000 mg 4 4 377 (171 to 582)  
Oral dose iron/study month
<4000 mg/month 6 6 259 (147 to 371) 0.54
Table 2.   Subgroup analysis and meta-regression to examine heterogeneity in ferritin meta-analyses    
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≥ 4000 to < 6000 mg/month 9 8 171 (149 to 193)  
≥ 6000 mg/month 7 5 225 (67 to 193)  
Dose oral iron (mg total dose) 
≥ 12,000 mg 7 7 244 (163 to 324) 0.82
1200 to 30,000 mg 10 7 158 (117 to 199)  
> 30,000 mg 7 6 303 (111 to 495)  
Any ESA use 
No EPO 9 3 214 (150 to 276) 0.62
EPO 19 18 243 (189 to 298)  
ESA timing of use 
Start of study 7 5 237 (153 to 322) 0.89
Before study 12 12 245 (144 to 546)  
CKD stage
1 to 5 9 7 229 (158 to 300) 0.73
Dialysis (5D) 18 16 247 (162 to 331)  
Study duration
≥ 2 months 10 9 215 (142 to 289) 0.43
> 2 to ≤ 4 months 7 6 268 (84 to 452)  
> 4 months 9 8 262 (169 to 355)  
Intervention aim
Increase Hb 24 20 336 (84 to 588) 0.12
Maintain Hb 4 4 282 (177 to 261)  
Pharmaceutical company sponsorship 
Unclear 16 15 257 (173 to 341) 0.52
Sponsored 12 9 224 (158 to 291)  
Imputed standard deviation
Not imputed   21 247 (187 to 307) 0.68
imputed   3 214 (86 to 341)  
Table 2.   Subgroup analysis and meta-regression to examine heterogeneity in ferritin meta-analyses     (Continued)
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CKD: chronic kidney disease; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin
 
 
  Total
studies
(N)
Studies MD (95% CI) (µg/L) P
Dose IV iron/study month
≥ 400 mg/month 9 5 16.78 (-0.22 to 33.78) 0.96
>400 -700 mg/month 5 4 2.20 (-5.0 to 9.40)  
>700 mg/month 8 6 8.69 (5.83 to 11.55)  
Dose IV iron (mg total dose)
≥ 1000 mg 8 6 7.60 (3.51 to 11.70) 0.10
1000 to 1999 mg 10 7 4.70 (-0.47 to 9.86)  
> 2000 mg 4 2 35.84 (-2.75 to 74.42)  
Oral dose iron/study month
< 4000 mg/month 6 5 7.57 (4.49 to 10.66) 0.38
≥4000 to < 6000 mg/month 9 6 7.98 (-0.48 to 16.45)  
≥ 6000 mg/month 7 4 5.97 (1.62 to 10.32)  
Dose oral iron (mg total dose)
≥ 12,000 mg 7 5 5.89 (3.21 to 8.57) 0.23
1200 to 30,000 mg 10 7 9.33 (-0.08 to 18.74)  
> 30,000 mg 7 4 18.32 (0.43 to 36.22)  
Any ESA use
No EPO 9 4 9.77 (4.89 to 14.65) 0.89
EPO 19 12 11.22 (3.51 to 18.93)  
ESA timing of use 
Start of study 7 4 6.78 (-4.68 to 14.65) 0.62
Before study 12 8 13.26 (3.16 to 23.36)  
CKD stage
1 to 5 9 6 6.89 (3.65 to 10.12) 0.35
Dialysis (5D) 18 11 13.69 (6.00 to 21.34)  
Table 3.   Subgroup analysis and meta-regression to examine heterogeneity in transferrin saturation meta-analyses 
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Study duration
≥ 2 months 10 7 5.81 (3.53 to 8.09) 0.77
> 2 to ≤ 4 months 7 7 17.36 (-1.03 to 35.74)  
> 4 months 9 4 6.30 (1.31 to 11.29)  
Intervention aim
Increase Hb 24 14 7.59 (4.07 to 17.11) 0.18
Maintain Hb 4 4 18.28 (-3.73 to 40.30)  
Pharmaceutical company sponsorship
Unclear 16 10 14.28 (4.21 to 24.34) 0.17
Sponsored 12 8 5.38 (3.06 to 7.71)  
Imputed standard deviation 
Not imputed   17 4.00 (0.38 to 7.62) 0.62
imputed   1 10.61 (5.67 to 15.55)  
Table 3.   Subgroup analysis and meta-regression to examine heterogeneity in transferrin saturation meta-
analyses  (Continued)
CKD: chronic kidney disease; ESA: erythropoiesis-stimulating agent; Hb: haemoglobin
 
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Ferric Compounds explode all trees
2. MeSH descriptor Ferrous Compounds explode all trees
3. MeSH descriptor Hematinics, this term only
4. MeSH descriptor Iron-Dextran Complex, this term only
5. MeSH descriptor Iron, this term only
6. MeSH descriptor Ferrosoferric Oxide, this term only
7. (iron and (gluconate* or fumarate* or dextran* or sucrose* or saccharate*)) in Clinical Trials
8. (iron and (supplement* or therap* or replacement)) in Clinical Trials
9. (ferric or ferrous) and gluconate* in Clinical Trials
10.(ferumoxytol or magnetite or "ferriferous oxide") in Clinical Trials
11.(1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10)
12.MeSH descriptor Renal Replacement Therapy explode all trees
13.MeSH descriptor Renal Insufficiency, this term only
14.MeSH descriptor Kidney Failure, this term only
15.MeSH descriptor Renal Insufficiency, Chronic explode all trees
16.MeSH descriptor Kidney Diseases, this term only
17.MeSH descriptor Uremia, this term only
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18.(hemodialysis or haemodialysis) in Clinical Trials
19.(hemofiltration or haemofiltration) in Clinical Trials
20.(hemodiafiltration or haemodiafiltration) in Clinical Trials
21.(dialysis) in Clinical Trials
22.(PD or CAPD or CCPD or APD) in Clinical Trials
23.(end-stage renal or end-stage kidney or endstage renal or endstage kidney) in Clinical Trials
24.(ESRF or ESKF or ESRD or ESKD) in Clinical Trials
25.(chronic kidney or chronic renal) in Clinical Trials
26.(CKF or CKD or CRF or CRD) in Clinical Trials
27.(ur?emi*.) in Clinical Trials
28.(ur?emi*) in Clinical Trials
29.(12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26
OR 27 OR 28)
30.(11 AND 29)
MEDLINE 1. exp Ferric Compounds/ or exp Ferrous Compounds/
2. Hematinics/
3. Iron-Dextran Complex/
4. Iron/
5. Ferrosoferric Oxide/
6. (iron and (gluconate$ or fumarate$ or dextran$ or sucrose$ or saccharate$)).tw.
7. (iron and (supplement$ or therap$ or replacement)).tw.
8. ((ferric or ferrous) and gluconate$).tw.
9. (ferumoxytol or magnetite or "ferriferous oxide").tw.
10.or/1-9
11.exp Renal Replacement Therapy/
12.(hemodialysis or haemodialysis).tw.
13.(hemofiltration or haemofiltration).tw.
14.(hemodiafiltration or haemodiafiltration).tw.
15.dialysis.tw.
16.(PD or CAPD or CCPD or APD).tw.
17.Renal Insufficiency/
18.Kidney Failure/
19.exp Renal Insufficiency, Chronic/
20.Kidney Diseases/
21.Uremia/
22.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
23.(ESRF or ESKF or ESRD or ESKD).tw.
24.(chronic kidney or chronic renal).tw.
25.(CKF or CKD or CRF or CRD).tw.
26.ur?emi$.tw.
27.or/11-26
28.and/10,27
EMBASE 1. Iron therapy/
2. antianemic agent/ or ferric citrate/ or ferric gluconate/ or ferric hydroxide sucrose/ or ferric mal-
tol/ or ferric pyrophosphate/ or ferrous ascorbate/ or ferrous aspartate/ or ferrous chloride/ or
ferrous fumarate/ or ferrous gluconate/ or ferrous succinate/ or ferrous sulfate/ or ferrous sulfate
plus folic acid/ or ferumoxytol/ or iron dextran/ or iron polymaltose/ or "iron poly(sorbitol glucon-
ic acid) complex"/ or iron protein succinylate/ or iron saccharate/ or iron salt/ or iron sorbitex/
3. Ferumoxytol/
4. (iron and (gluconate$ or fumarate$ or dextran$ or sucrose$ or saccharate$)).tw.
  (Continued)
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5. (iron and (supplement$ or therap$ or replacement)).tw.
6. ((ferric or ferrous) and gluconate$).tw.
7. (ferumoxytol or magnetite or "ferriferous oxide").tw.
8. or/1-7
9. exp Renal Replacement Therapy/
10.(hemodialysis or haemodialysis).tw.
11.(hemofiltration or haemofiltration).tw.
12.(hemodiafiltration or haemodiafiltration).tw.
13.dialysis.tw.
14.(PD or CAPD or CCPD or APD).tw.
15.Kidney Disease/
16.Chronic Kidney Disease/
17.Kidney Failure/
18.Chronic Kidney Failure/
19.Uremia/
20.(chronic kidney or chronic renal).tw.
21.(CKF or CKD or CRF or CRD).tw.
22.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
23.(ESRF or ESKF or ESRD or ESKD).tw.
24.ur?emi$.tw.
25.or/9-24
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Unclear: Randomisation stated but no information on method used is available.
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Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Selective reporting
Reporting bias due to selective
outcome reporting
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of bias.
  (Continued)
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High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
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3. Extract data from studies: JA, EH
4. Enter data into RevMan: JA, EH
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6. Interpret the analysis: JA, EH, AW, JC
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9. Update the review: JA, EH, AW, JC
D E C L A R A T I O N S   O F   I N T E R E S T
None known
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Administration, Oral;  Anemia, Iron-Deficiency  [blood]  [*therapy];  Ferritins  [blood];  Hemoglobin A  [metabolism];  Injections,
Intravenous;  Iron Compounds  [*administration & dosage];  Kidney Failure, Chronic  [blood]  [*complications];  Randomized Controlled
Trials as Topic;  Transferrin  [metabolism]
MeSH check words
Adult; Child; Humans
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